


**CUMULATIVE  
SUPPLEMENT 4**  
April 2012



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**32nd EDITION**

**Department of Health and Human Services**  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Generic Drugs

2012

Prepared By  
Office of Generic Drugs  
Center for Drug Evaluation and Research  
Food and Drug Administration

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**32<sup>nd</sup> EDITION**

**Cumulative Supplement 4**

**April 2012**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION .....	iii
1.1 How to use the Cumulative Supplement .....	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition .....	vi
1.6 Report of Counts for the Prescription Drug Product List .....	vii
1.7 Cumulative Supplement Legend .....	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**32nd EDITION**

**CUMULATIVE SUPPLEMENT 4  
April 2012**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [drugproducts@fda.hhs.gov](mailto:drugproducts@fda.hhs.gov). Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff  
Office of Generic Drugs, HFD-610  
7620 Standish Place  
Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> (FORMER ABBREVIATED NAME)	<u>NEW APPLICANT NAME</u> (NEW ABBREVIATED NAME)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHEROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use



in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST  
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711			
SINGLE SOURCE	2451 (16.9%)	2446 (16.6%)			
MULTISOURCE	11953 (82.5%)	12187 (82.8%)			
THERAPEUTICALLY EQUIVALENT	11792 (81.4%)	12037 (81.8%)			
NOT THERAPEUTICALLY EQUIVALENT	161 (1.1%)	150 (1.0%)			
EXCEPTIONS <sup>1</sup>	76 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	6	8			
NUMBER OF APPLICANTS	810	826			

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

1-1

ACARBOSE

TABLET; ORAL

ACARBOSE

AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
----	---------------	--------------------	-------------	--	-----	------

SUSPENSION; ORAL

CAPITAL AND CODEINE

+ VALEANT

120MG/5ML;12MG/5ML

A086024 001		Jan	CTEC
-------------	--	-----	------

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
----	------------	-----------------------	-------------	--------------	-----	------

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	ACTAVIS TOTOWA	325MG;7.5MG	A040800 001	Apr 03, 2012	Mar	NEWA
AA		325MG;10MG	A040800 002	Apr 03, 2012	Mar	NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALVOGEN INC	325MG;37.5MG	A202076 001	Mar 30, 2012	Mar	NEWA
----	-------------	--------------	-------------	--------------	-----	------

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

>A>	AP	SAGENT STRIDES	EQ 500MG BASE/VIAL	A200880 001	May 09, 2012	Apr	NEWA
>D>	AP	X GEN PHARMS	EQ 500MG BASE/VIAL	A040784 001	Dec 10, 2008	Apr	CRLD
>A>	AP	+	EQ 500MG BASE/VIAL	A040784 001	Dec 10, 2008	Apr	CRLD
>D>		DIAMOX					
>D>	AP	+ DURAMED PHARMS BARR	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990	Apr	DISC
>A>		@ TEVA WOMENS	EQ 500MG BASE/VIAL	N009388 001	Dec 05, 1990	Apr	DISC

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB	FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

>A>	+	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010	Apr	CAHN
-----	---	------------------	------	-------------	--------------	-----	------

	LOTION; TOPICAL								
	DIFFERIN								
>D>	+ GALDERMA R AND D	0.1%			N022502	001	Mar 17, 2010	Apr	CAHN
<u>ADENOSINE</u>									
	INJECTABLE; INJECTION								
	ADENOSINE								
	@ TEVA PARENTERAL	3MG/ML			A078676	001	Jul 31, 2008	Mar	DISC
	@	3MG/ML			A076564	001	Jun 16, 2004	Jan	DISC
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>									
	SOLUTION; INHALATION								
	ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE								
>D>	AN SANDOZ	EQ 0.083% BASE;0.017%			A076867	001	Dec 21, 2006	Apr	DISC
>A>	@ SANDOZ INC	EQ 0.083% BASE;0.017%			A076867	001	Dec 21, 2006	Apr	DISC
<u>ALCLOMETASONE DIPROPIONATE</u>									
	CREAM; TOPICAL								
	ALCLOMETASONE DIPROPIONATE								
AB	FOUGERA PHARMS	0.05%			A076973	001	Jul 12, 2005	Jan	CAHN
	OINTMENT; TOPICAL								
	ALCLOMETASONE DIPROPIONATE								
AB	FOUGERA PHARMS	0.05%			A076884	001	Jul 18, 2005	Jan	CAHN
<u>ALENDRONATE SODIUM</u>									
	TABLET, EFFERVESCENT; ORAL								
	BINOSTO								
	+ MISSION PHARMA	EQ 70MG BASE			N202344	001	Mar 12, 2012	Mar	NEWA
<u>ALFUZOSIN HYDROCHLORIDE</u>									
	TABLET, EXTENDED RELEASE; ORAL								
	ALFUZOSIN HYDROCHLORIDE								
AB	INVAGEN PHARMS	10MG			A090284	001	Jan 17, 2012	Jan	NEWA
<u>ALGLUCERASE</u>									
	INJECTABLE; INJECTION								
	CEREDASE								
	@ GENZYME	80 UNITS/ML			N020057	003	Apr 05, 1991	Mar	DISC
<u>ALPRAZOLAM</u>									
	TABLET, EXTENDED RELEASE; ORAL								
	ALPRAZOLAM								
	@ SANDOZ INC	0.5MG			A077777	001	Jun 30, 2006	Mar	DISC
	@	1MG			A077777	002	Jun 30, 2006	Mar	DISC
	@	2MG			A077777	003	Jun 30, 2006	Mar	DISC
	@	3MG			A077777	004	Jun 30, 2006	Mar	DISC
	TABLET, ORALLY DISINTEGRATING; ORAL								
	NIRAVAM								
AB	UCB INC	0.25MG			N021726	001	Jan 19, 2005	Jan	CAHN
AB		0.5MG			N021726	002	Jan 19, 2005	Jan	CAHN
AB	+	1MG			N021726	003	Jan 19, 2005	Jan	CAHN
AB		2MG			N021726	004	Jan 19, 2005	Jan	CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+ CUBIST PHARMS 12MG N021775 001 May 20, 2008 Feb CAHN

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS 0.1% A076065 001 May 15, 2003 Jan CAHN

LOTION; TOPICAL

AMCINONIDE

+ FOUGERA PHARMS 0.1% A076329 001 Nov 06, 2002 Jan CAHN

OINTMENT; TOPICAL

AMCINONIDE

AB + FOUGERA PHARMS 0.1% A076096 001 Nov 19, 2002 Jan CAHN

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN

15% (150GM/1000ML)

A091112 001 Apr 13, 2012 Mar NEWA

15% (300GM/2000ML)

A091112 002 Apr 13, 2012 Mar NEWA

NOVAMINE 15%

@ HOSPIRA INC

15% (75GM/500ML)

N017957 004 Nov 28, 1986 Mar CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS

250MG/ML

N015229 002 Mar CAHN

SYRUP; ORAL

AMICAR

AA + CLOVER PHARMS 1.25GM/5ML N015230 002 Mar CAHN

TABLET; ORAL

AMICAR

AB CLOVER PHARMS 500MG N015197 001 Mar CAHN

+

1GM

N015197 002 Jun 24, 2004 Mar CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ TEVA PARENTERAL

50MG/ML

A076163 001 Sep 05, 2003 Jan DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

&gt;A&gt; AB CARACO 10MG A040816 002 Jun 27, 2008 Apr NEWA

&gt;A&gt; AB 50MG A040816 003 Jun 27, 2008 Apr NEWA

&gt;A&gt; AB 75MG A040816 004 Jun 27, 2008 Apr NEWA

&gt;A&gt; AB 100MG A040816 005 Jun 27, 2008 Apr NEWA

&gt;A&gt; AB 150MG A040816 006 Jun 27, 2008 Apr NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

MYLAN PHARMS INC

EQ 12.5MG BASE;5MG

A071297 002 Dec 10, 1986 Feb CTEC

+

EQ 25MG BASE;10MG

A071297 001 Dec 10, 1986 Feb CRLD

## TABLET; ORAL

## LIMBITROL

@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001	Feb	DISC
----------------------	--------------------	-------------	-----	------

## LIMBITROL DS

@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002	Feb	DISC
----------------------	-------------------	-------------	-----	------

AMLODIPINE BESYLATE

## TABLET; ORAL

## AMLODIPINE BESYLATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
----	---------------------	-------------	-------------	--------------	-----	------

AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA
----	--	--------------	-------------	--------------	-----	------

AMOXICILLIN

## TABLET, FOR SUSPENSION; ORAL

## DISPERMOX

>D>						
-----	--	--	--	--	--	--

>D>	+	RANBAXY	600MG	A065159 001	Dec 04, 2003	Apr	DISC
-----	---	---------	-------	-------------	--------------	-----	------

>A>		@ RANBAXY LABS LTD	600MG	A065159 001	Dec 04, 2003	Apr	DISC
-----	--	--------------------	-------	-------------	--------------	-----	------

AMOXICILLIN; CLAVULANATE POTASSIUM

## TABLET; ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
----	----------------------	---------------------	-------------	--------------	-----	------

AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
----	--	---------------------	-------------	--------------	-----	------

AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA
----	--	---------------------	-------------	--------------	-----	------

ANAGRELIDE HYDROCHLORIDE

## CAPSULE; ORAL

## AGRYLIN

AB	SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
----	-----------	---------------	-------------	--------------	-----	------

## ANAGRELIDE HYDROCHLORIDE

@ SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC
--------------	---------------	-------------	--------------	-----	------

@	EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC
---	-------------	-------------	--------------	-----	------

ANASTROZOLE

## TABLET; ORAL

## ANASTROZOLE

>A>	AB	APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
-----	----	------------	-----	-------------	--------------	-----	------

ARGATROBAN

## INJECTABLE; INJECTION

## ACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
----	---	--------	------------------------	-------------	--------------	-----	------

## ARGATROBAN

AP		HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA
----	--	--------------------	------------------------	-------------	--------------	-----	------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

## FOR SOLUTION; ORAL

## ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA		NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9MG;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan	NEWA
----	--	----------------	--	-------------	--------------	-----	------

## MOVIPREP

AA	+	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan	CFTG
----	---	--------------	--	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB	PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN
----	-------------	-------------	---------	-----	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN
----	-------------	------------------	---------	-----	--------------	-----	------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901	001	Jul 18, 1997	Feb	CTEC
----	---	---------	---------	---------	-----	--------------	-----	------

AP		SAGENT PHARMS	10MG/ML	A091489	001	Feb 17, 2012	Feb	NEWA
----	--	---------------	---------	---------	-----	--------------	-----	------

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	+	BEDFORD	10MG/ML	A074900	001	Jul 18, 1997	Feb	CTEC
----	---	---------	---------	---------	-----	--------------	-----	------

AP		SAGENT PHARMS	10MG/ML	A091488	001	Feb 17, 2012	Feb	NEWA
----	--	---------------	---------	---------	-----	--------------	-----	------

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

>D>	AA	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Apr	CRLD
-----	----	--------	-----------------------	---------	-----	--------------	-----	------

>A>	AA	+	0.025MG/5ML;2.5MG/5ML	A087708	001	May 03, 1982	Apr	CRLD
-----	----	---	-----------------------	---------	-----	--------------	-----	------

>D>		LOMOTIL						
-----	--	---------	--	--	--	--	--	--

>D>	AA	+	GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699	001		Apr	DISC
-----	----	---	---------------	-----------------------	---------	-----	--	-----	------

>A>		@		0.025MG/5ML;2.5MG/5ML	N012699	001		Apr	DISC
-----	--	---	--	-----------------------	---------	-----	--	-----	------

>A> AVANAFIL

>A>		TABLET; ORAL						
-----	--	--------------	--	--	--	--	--	--

>A>		STENDRA						
-----	--	---------	--	--	--	--	--	--

>A>		VIVUS	50MG	N202276	001	Apr 27, 2012	Apr	NEWA
-----	--	-------	------	---------	-----	--------------	-----	------

>A>			100MG	N202276	002	Apr 27, 2012	Apr	NEWA
-----	--	--	-------	---------	-----	--------------	-----	------

>A>		+	200MG	N202276	003	Apr 27, 2012	Apr	NEWA
-----	--	---	-------	---------	-----	--------------	-----	------

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

1MG

N202324	001	Jan 27, 2012	Jan	NEWA
---------	-----	--------------	-----	------

+

5MG

N202324	002	Jan 27, 2012	Jan	NEWA
---------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

>D>		TAKEDA PHARMS	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CAHN
-----	--	---------------	-------------------	---------	-----	--------------	-----	------

>D>		+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CAHN
-----	--	---	-------------------	---------	-----	--------------	-----	------

>A>		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Apr	CAHN
-----	--	-------------------	-------------------	---------	-----	--------------	-----	------

>A>		+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Apr	CAHN
-----	--	---	-------------------	---------	-----	--------------	-----	------

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

>D>		TAKEDA PHARMS	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Apr	CAHN
-----	--	---------------	--------------------------	---------	-----	--------------	-----	------

>D>		+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Apr	CAHN
-----	--	---	------------------------	---------	-----	--------------	-----	------

>A>		TAKEDA PHARMS USA	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Apr	CAHN
-----	--	-------------------	--------------------------	---------	-----	--------------	-----	------

TABLET; ORAL  
EDARBYCLOR  
>A> + TAKEDA PHARMS USA EQ 40MG MEDOXOMIL; 25MG N202331 002 Dec 20, 2011 Apr CAHN

BACLOFEN

TABLET; ORAL  
BACLOFEN  
AB PROSAM LABS 10MG A077089 001 Oct 31, 2007 Feb CAHN  
AB 20MG A077088 001 Oct 31, 2007 Feb CAHN  
TABLET, ORALLY DISINTEGRATING; ORAL  
KEMSTRO  
@ UCB INC 10MG N021589 001 Oct 30, 2003 Jan CAHN  
@ 20MG N021589 002 Oct 30, 2003 Jan CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL  
GLAZO  
+ SALIX PHARMS 1.1GM N022205 001 Feb 03, 2012 Feb NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL  
QNASL  
+ TEVA BRANDED PHARM 0.08MG/ACTIVATION N202813 001 Mar 23, 2012 Mar NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL  
BENZACLIN  
>D> BT + SANOFI AVENTIS US 5%;EQ 1% BASE N050756 002 Apr 20, 2007 Apr CAHN  
>D> AB 5%;EQ 1% BASE N050756 001 Dec 21, 2000 Apr CAHN  
>A> AB VALEANT INTL 5%;EQ 1% BASE N050756 001 Dec 21, 2000 Apr CAHN  
>A> BT + 5%;EQ 1% BASE N050756 002 Apr 20, 2007 Apr CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL  
BENZAMYCIN  
AB + VALEANT INTL 5%;3% N050557 001 Oct 26, 1984 Jan CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL  
BENZPHETAMINE HYDROCHLORIDE  
AA EMCURE PHARMS LTD 50MG A202061 001 Jan 27, 2012 Jan NEWA

BENZTROPINE MESYLATE

INJECTABLE; INJECTION  
COGENTIN  
AP + OAK PHARMS AKORN 1MG/ML N012015 001 Feb CAHN  
TABLET; ORAL  
BENZTROPINE MESYLATE  
@ LANNETT HOLDINGS INC 0.5MG A088877 001 Apr 11, 1985 Jan DISC  
@ 1MG A088894 001 Apr 11, 1985 Jan DISC  
@ 2MG A088895 001 Apr 11, 1985 Jan DISC  
AA PROSAM LABS 0.5MG A040699 001 Feb 14, 2008 Feb CMFD  
AA 1MG A040705 001 Feb 14, 2008 Feb CMFD  
AA 2MG A040706 001 Feb 14, 2008 Feb CMFD  
AA + USL PHARMA 0.5MG A040103 001 Dec 12, 1996 Jan CRLD  
AA + 1MG A040103 002 Dec 12, 1996 Jan CRLD



## TABLET; ORAL

BENZTROPINE MESYLATE

AA	+	USL PHARMA	2MG	A040103	003	Dec 12, 1996	Jan	CRLD
----	---	------------	-----	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

## CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

## CREAM, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

## GEL, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003	Jan	CAHN
----	---	----------------	---------------	---------	-----	--------------	-----	------

## LOTION, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

## OINTMENT, AUGMENTED; TOPICAL

BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999	Jan	CAHN
----	--	----------------	---------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

## CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001	Jan	CAHN
----	--	----------------	------------------	---------	-----	--------------	-----	------

## LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005	Jan	CAHN
----	--	----------------	------------------	---------	-----	--------------	-----	------

LOTISON

AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	CAHN
----	---	---------------	------------------	---------	-----	--------------	-----	------

BETAMETHASONE VALERATE

## AEROSOL, FOAM; TOPICAL

LUXIQ

	+	STIEFEL	EQ 0.12% BASE	N020934	001	Feb 28, 1999	Jan	CAHN
--	---	---------	---------------	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

## TABLET; ORAL

ZEBETA

AB		TEVA WOMENS	5MG	N019982	002	Jul 31, 1992	Jan	CAHN
----	--	-------------	-----	---------	-----	--------------	-----	------

AB	+		10MG	N019982	001	Jul 31, 1992	Jan	CAHN
----	---	--	------	---------	-----	--------------	-----	------

BOCEPREVIR

## CAPSULE; ORAL

VICTRELIS

	+	MERCK SHARP DOHME	200MG	N202258	001	May 13, 2011	Mar	CAHN
--	---	-------------------	-------	---------	-----	--------------	-----	------

BORTEZOMIB

## INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

VELCADE

	+	MILLENNIUM PHARMS	3.5MG/VIAL	N021602	001	May 13, 2003	Jan	CDFR
--	---	-------------------	------------	---------	-----	--------------	-----	------

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

## AEROSOL, METERED; INHALATION

SYMBICORT

	+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929	001	Jul 21, 2006	Jan	CDFR
--	---	-------------	-------------------------	---------	-----	--------------	-----	------

## AEROSOL, METERED; INHALATION

## SYMBICORT

+ ASTRAZENECA	0.16MG/INH;0.0045MG/INH	N021929 002	Jul 21, 2006	Jan	CDFR
---------------	-------------------------	-------------	--------------	-----	------

>A> BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

&gt;A&gt; FILM; SUBLINGUAL

&gt;A&gt; SUBOXONE

>A> RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
-----------------------	---------------------------	-------------	--------------	-----	------

>A> +	EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN
-------	-------------------------	-------------	--------------	-----	------

TABLET; SUBLINGUAL

SUBOXONE

>D> RECKITT BENCKISER	2MG;0.5MG	N020733 001	Oct 08, 2002	Apr	CPOT
-----------------------	-----------	-------------	--------------	-----	------

>A>	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
-----	---------------------------	-------------	--------------	-----	------

>D> +	8MG;2MG	N020733 002	Oct 08, 2002	Apr	CPOT
-------	---------	-------------	--------------	-----	------

>A> +	EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT
-------	-------------------------	-------------	--------------	-----	------

>D> BUPRENORPHINE; NALOXONE

&gt;D&gt; FILM; SUBLINGUAL

&gt;D&gt; SUBOXONE

>D> RECKITT BENCKISER	2MG;0.5MG	N022410 001	Aug 30, 2010	Apr	CAIN
-----------------------	-----------	-------------	--------------	-----	------

>D> +	8MG;2MG	N022410 002	Aug 30, 2010	Apr	CAIN
-------	---------	-------------	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FORFIVO XL

+ EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
-----------------------	-------	-------------	--------------	-----	------

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
----------	-----	-------------	--------------	-----	------

@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
---	------	-------------	--------------	-----	------

@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
---	------	-------------	--------------	-----	------

@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
--------	-----	-------------	--------------	-----	------

@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
---	------	-------------	--------------	-----	------

@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
---	------	-------------	--------------	-----	------

@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
---------------	-----	-------------	--------------	-----	------

AB	5MG	A075388 001	May 09, 2002	Feb	CMFD
----	-----	-------------	--------------	-----	------

@	10MG	A075388 002	May 09, 2002	Mar	DISC
---	------	-------------	--------------	-----	------

AB	10MG	A075388 002	May 09, 2002	Feb	CMFD
----	------	-------------	--------------	-----	------

@	15MG	A075388 003	May 09, 2002	Mar	DISC
---	------	-------------	--------------	-----	------

AB	15MG	A075388 003	May 09, 2002	Feb	CMFD
----	------	-------------	--------------	-----	------

AB	30MG	A078302 001	Dec 17, 2007	Feb	CMFD
----	------	-------------	--------------	-----	------

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

&gt;A&gt; BUTOCONAZOLE NITRATE

>A> @ PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Apr	NEWA
----------------------	----	-------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP + BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
-------------------	------------------------------------	-------------	--------------	-----	------

## SOLUTION; ORAL

## CAFCIT

AA	+	BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	---	--------------	---------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

## SOLUTION; TOPICAL

## CALCIPOTRIENE

AT		FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	--	----------------	--------	-------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

## TABLET; ORAL

## CARBIDOPA, LEVODOPA AND ENTACAPONE

>A>	AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
>A>	AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA
		STALEVO 100					
>D>		ORION	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
>A>	AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
		STALEVO 150					
>D>		ORION	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG
>A>	AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG

CARBIDOPA; LEVODOPA

## TABLET, ORALLY DISINTEGRATING; ORAL

## PARCOPA

AB		UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
AB			25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
AB	+		25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

## INJECTABLE; INJECTION

## CARBOPLATIN

AP		CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP			150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP			450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
		PARAPLATIN					
		@ CORDEN PHARMA	50MG/VIAL	N019880 001	Mar 03, 1989	Feb	CAHN
		@	150MG/VIAL	N019880 002	Mar 03, 1989	Feb	CAHN
		@	450MG/VIAL	N019880 003	Mar 03, 1989	Feb	CAHN

## INJECTABLE; IV (INFUSION)

## CARBOPLATIN

AP		ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP			150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP			450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP			600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP		CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP			150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP			450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP			600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARISOPRODOL

## TABLET; ORAL

## CARISOPRODOL

AA		PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	--	-------------	-------	-------------	--------------	-----	------

CEFACTOR

## CAPSULE; ORAL

## CEFACTOR

>D>	AB	RANBAXY	EQ 250MG BASE	A064156 001	Aug 28, 1997	Apr	DISC
>A>		@	EQ 250MG BASE	A064156 001	Aug 28, 1997	Apr	DISC
>D>	AB		EQ 500MG BASE	A064156 002	Aug 28, 1997	Apr	DISC
>A>		@	EQ 500MG BASE	A064156 002	Aug 28, 1997	Apr	DISC

## FOR SUSPENSION; ORAL

## CEFACTOR

>D>	AB	+	RANBAXY	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
>D>	AB	+		EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
>D>	AB	+		EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
>D>	AB	+		EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC
>A>			@	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC
	AB	+		EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Feb	CTEC
	AB		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412 001	Feb 17, 2012	Feb	NEWA
	AB			EQ 187MG BASE/5ML	A065412 002	Feb 17, 2012	Feb	NEWA
	AB			EQ 250MG BASE/5ML	A065412 003	Feb 17, 2012	Feb	NEWA
	AB			EQ 375MG BASE/5ML	A065412 004	Feb 17, 2012	Feb	NEWA

## TABLET, CHEWABLE; ORAL

## RANICLOR

>D>			RANBAXY	EQ 125MG BASE	A065092 001	Dec 22, 2003	Apr	DISC
>D>				EQ 187MG BASE	A065092 002	Dec 22, 2003	Apr	DISC
>D>				EQ 250MG BASE	A065092 003	Dec 22, 2003	Apr	DISC
>D>			+	EQ 375MG BASE	A065092 004	Dec 22, 2003	Apr	DISC
>A>			@ RANBAXY LABS LTD	EQ 125MG BASE	A065092 001	Dec 22, 2003	Apr	DISC
>A>			@	EQ 187MG BASE	A065092 002	Dec 22, 2003	Apr	DISC
>A>			@	EQ 250MG BASE	A065092 003	Dec 22, 2003	Apr	DISC
>A>			+ @	EQ 375MG BASE	A065092 004	Dec 22, 2003	Apr	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

## CAPSULE; ORAL

## CEFADROXIL

>D>	AB		RANBAXY	EQ 500MG BASE	A065015 001	Jun 22, 1999	Apr	DISC
>A>			@ RANBAXY LABS LTD	EQ 500MG BASE	A065015 001	Jun 22, 1999	Apr	DISC

## TABLET; ORAL

## CEFADROXIL

>D>	AB		RANBAXY	EQ 1GM BASE	A065018 001	Apr 23, 1999	Apr	DISC
>A>			@	EQ 1GM BASE	A065018 001	Apr 23, 1999	Apr	DISC

CEFDITOREN PIVOXIL

## TABLET; ORAL

## SPECTRACEF

## VANSEN PHARMA

+

			200MG	N021222 001	Aug 29, 2001	Mar	CAHN
			400MG	N021222 002	Jul 21, 2008	Mar	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB		APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB			250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
>D>	AB	RANBAXY	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
>D>	AB		250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC
>A>		@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
>A>		@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

CEFPROZIL

>D>	AB	RANBAXY	250MG	A065198 001	Dec 13, 2006	Apr	DISC
>D>	AB		500MG	A065198 002	Dec 13, 2006	Apr	DISC
>A>		@ RANBAXY LABS LTD	250MG	A065198 001	Dec 13, 2006	Apr	DISC
>A>		@	500MG	A065198 002	Dec 13, 2006	Apr	DISC
		CEFZIL					
		@ CORDEN PHARMA	250MG	N050664 001	Dec 23, 1991	Feb	CAHN
		@	500MG	N050664 002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

>A>	AP	+	COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
>A>	AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
>A>	AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
>A>	AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN
>D>	AP	+	GLAXOSMITHKLINE	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
>D>	AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
>D>	AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
>D>	AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

>A>		@ COVIS PHARMA	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989	Apr	CAHN
>A>		+	EQ 20MG BASE/ML	N050634 002	Apr 28, 1989	Apr	CAHN
>A>		+	EQ 40MG BASE/ML	N050634 003	Apr 28, 1989	Apr	CAHN
>D>		@ GLAXOSMITHKLINE	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989	Apr	CAHN
>D>		+	EQ 20MG BASE/ML	N050634 002	Apr 28, 1989	Apr	CAHN
>D>		+	EQ 40MG BASE/ML	N050634 003	Apr 28, 1989	Apr	CAHN

CEFTRIAZONE SODIUM

INJECTABLE; INJECTION

CEFTRIAZONE

AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

>D>	AB	RANBAXY	EQ 125MG BASE	A065043 003	Feb 15, 2002	Apr	DISC
>D>	AB		EQ 250MG BASE	A065043 002	Feb 15, 2002	Apr	DISC
>D>	AB		EQ 500MG BASE	A065043 001	Feb 15, 2002	Apr	DISC
>A>		@ RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002	Apr	DISC
>A>		@	EQ 250MG BASE	A065043 002	Feb 15, 2002	Apr	DISC
>A>		@	EQ 500MG BASE	A065043 001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

ZINACEF

>A>	AB	+	COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
>D>	AB	+	GLAXOSMITHKLINE	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN

INJECTABLE; INJECTION

ZINACEF

>A>	AP	+	COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
>A>	AP	+		EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
>D>	AP	+	GLAXOSMITHKLINE	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN
>D>	AP	+		EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN

ZINACEF IN PLASTIC CONTAINER

>A>		+	COVIS PHARMA	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989	Apr	CAHN
>A>		+		EQ 30MG BASE/ML	N050643 002	Apr 28, 1989	Apr	CAHN
>D>		+	GLAXOSMITHKLINE	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989	Apr	CAHN
>D>		+		EQ 30MG BASE/ML	N050643 002	Apr 28, 1989	Apr	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>A>	AA		SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA
-----	----	--	--------	---------	-------------	--------------	-----	------

CICLESONIDE

AEROSOL, METERED; NASAL

ZETONNA

		+	NYCOMED GMBH	0.037MG/INH	N202129 001	Jan 20, 2012	Jan	NEWA
--	--	---	--------------	-------------	-------------	--------------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB			FOUGERA PHARMS	0.77%	A076435 001	Dec 29, 2004	Jan	CAHN
----	--	--	----------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CICLOPIROX

AB			FOUGERA PHARMS	0.77%	A077896 001	Jun 10, 2008	Jan	CAHN
AB			GLENMARK GENERICS	0.77%	A091595 001	Feb 29, 2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

AT			FOUGERA PHARMS	1%	A090146 001	May 25, 2010	Jan	CAHN
----	--	--	----------------	----	-------------	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

AT			MYLAN PHARMS INC	8%	A078567 001	Sep 18, 2007	Feb	CAHN
----	--	--	------------------	----	-------------	--------------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB			FOUGERA PHARMS	0.77%	A076422 001	Aug 06, 2004	Jan	CAHN
----	--	--	----------------	-------	-------------	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782	001	Aug 28, 2006	Mar	DISC
@		400MG/40ML (10MG/ML)	A077782	002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	PLIVA	EQ 100MG BASE	A076426	001	Jun 15, 2005	Jan	DISC
@		EQ 250MG BASE	A076426	002	Jun 15, 2005	Jan	DISC
@		EQ 500MG BASE	A076426	003	Jun 15, 2005	Jan	DISC
@		EQ 750MG BASE	A076426	004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

\*\*\*\*\*; ORAL

CIPROFLOXACIN EXTENDED RELEASE

>A>	AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701	002	Oct 31, 2007	Apr	NEWA
-----	----	--------------------	-------------------------	---------	-----	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP		SANDOZ INC	EQ 2MG BASE/ML	A200159	001	Feb 03, 2012	Jan	NEWA
		CISATRACURIUM BESYLATE PRESERVATIVE FREE						
AP		SANDOZ INC	EQ 2MG BASE/ML	A200154	001	Feb 03, 2012	Jan	NEWA
AP			EQ 10MG BASE/ML	A200154	002	Feb 03, 2012	Jan	NEWA
		NIMBEX						
AP	+	ABBOTT	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Jan	CFTG
		NIMBEX PRESERVATIVE FREE						
AP	+	ABBOTT	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Jan	CFTG
AP	+		EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

>A>	AP	ONCO THERAPIES LTD	1MG/ML	A091062	001	Apr 18, 2012	Apr	NEWA
		@ TEVA PARENTERAL	1MG/ML	A074814	001	May 16, 2000	Mar	DISC

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 2% BASE	A065139	001	Dec 27, 2004	Jan	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Jan	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A065067	001	Jan 31, 2002	Jan	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT		FOUGERA PHARMS	EQ 1% BASE	A065254	001	Feb 14, 2006	Jan	CAHN
----	--	----------------	------------	---------	-----	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

	LUNDBECK LLC	5MG	N202067 001	Oct 21, 2011	Mar	CAHN
		10MG	N202067 002	Oct 21, 2011	Mar	CAHN
+		20MG	N202067 003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB1	+ FOUGERA PHARMS	0.05%	N019322 001	Dec 27, 1985	Jan	CAHN
-----	------------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A075368 001	Feb 15, 2000	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N020337 001	Apr 29, 1994	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A074407 001	Feb 23, 1996	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N019323 001	Dec 27, 1985	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AT	+ FOUGERA PHARMS	0.05%	N019966 001	Feb 22, 1990	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615 001	Oct 02, 1996	Feb	CAHN
----	---------------------	------------------------	-------------	--------------	-----	------

AP	+	5 MG/10 ML (0.5 MG/ML)	N020615 002	Apr 27, 1999	Feb	CAHN
----	---	------------------------	-------------	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

>A>	AB	APOTEX INC	EQ 300MG BASE	A076274 002	May 17, 2012	Apr	NEWA
-----	----	------------	---------------	-------------	--------------	-----	------

>A>	AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540 001	May 17, 2012	Apr	NEWA
-----	----	----------------------	--------------	-------------	--------------	-----	------

	AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273 001	Jan 14, 2008	Mar	CMFD
--	----	--------------------	--------------	-------------	--------------	-----	------

>A>	AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023 001	May 17, 2012	Apr	NEWA
-----	----	--------------------	---------------	-------------	--------------	-----	------

>A>	AB	GATE PHARMS	EQ 300MG BASE	A091216 001	May 17, 2012	Apr	NEWA
-----	----	-------------	---------------	-------------	--------------	-----	------

>A>	AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665 001	May 17, 2012	Apr	NEWA
-----	----	------------------	--------------	-------------	--------------	-----	------

>A>	AB		EQ 300MG BASE	A077665 002	May 17, 2012	Apr	NEWA
-----	----	--	---------------	-------------	--------------	-----	------

>A>	AB	ROXANE	EQ 75MG BASE	A078004 001	May 17, 2012	Apr	NEWA
-----	----	--------	--------------	-------------	--------------	-----	------

>A>	AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494 001	May 17, 2012	Apr	NEWA
-----	----	-------------------	--------------	-------------	--------------	-----	------

>A>	AB	TEVA	EQ 75MG BASE	A076999 001	May 17, 2012	Apr	NEWA
-----	----	------	--------------	-------------	--------------	-----	------

>A>	AB	TEVA PHARMS	EQ 300MG BASE	A090625 001	May 17, 2012	Apr	NEWA
-----	----	-------------	---------------	-------------	--------------	-----	------

>A>	AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844 001	May 17, 2012	Apr	NEWA
-----	----	--------------------	--------------	-------------	--------------	-----	------

PLAVIX

	AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997	Mar	CTEC
--	----	-------------------	--------------	-------------	--------------	-----	------

>D>		+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr	CTEC
-----	--	---	---------------	-------------	--------------	-----	------

>A>	AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr	CTEC
-----	----	---	---------------	-------------	--------------	-----	------



CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ LUNDBECK LLC

3.75MG

N017105 001

Mar CAHN

@

7.5MG

N017105 002

Mar CAHN

@

15MG

N017105 003

Mar CAHN

TABLET; ORAL

TRANXENE

AB LUNDBECK LLC

3.75MG

N017105 006

Mar CAHN

AB

7.5MG

N017105 007

Mar CAHN

AB +

15MG

N017105 008

Mar CAHN

TRANXENE SD

@ LUNDBECK LLC

11.25MG

N017105 005

Mar CAHN

@

22.5MG

N017105 004

Mar CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

AB FOUGERA PHARMS

1%

A078338 001 Sep 02, 2008 Jan CAHN

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

&gt;D&gt; AZUR PHARMA INTL

12.5MG

N021590 004 May 30, 2007 Apr CAHN

&gt;D&gt;

25MG

N021590 001 Feb 10, 2004 Apr CAHN

&gt;D&gt;

@

50MG

N021590 003 Jun 03, 2005 Apr CAHN

&gt;D&gt;

+

100MG

N021590 002 Feb 10, 2004 Apr CAHN

&gt;D&gt;

150MG

N021590 005 Jul 09, 2010 Apr CAHN

&gt;D&gt;

200MG

N021590 006 Jul 09, 2010 Apr CAHN

&gt;A&gt;

JAZZ

12.5MG

N021590 004 May 30, 2007 Apr CAHN

&gt;A&gt;

25MG

N021590 001 Feb 10, 2004 Apr CAHN

&gt;A&gt;

@

50MG

N021590 003 Jun 03, 2005 Apr CAHN

&gt;A&gt;

+

100MG

N021590 002 Feb 10, 2004 Apr CAHN

&gt;A&gt;

150MG

N021590 005 Jul 09, 2010 Apr CAHN

&gt;A&gt;

200MG

N021590 006 Jul 09, 2010 Apr CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL

GASTROCROM

AA + JAZZ PHARMS COMMERCL 100MG/5ML

N020479 001 Feb 29, 1996 Mar CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB PROSAM LABS

5MG

A077291 001 Feb 03, 2006 Feb CAHN

AB

10MG

A077209 001 Oct 04, 2005 Feb CAHN

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

&gt;D&gt; AP BAXTER HLTHCARE

500MG/VIAL

N012142 003

Apr CRLD

&gt;A&gt;

+

500MG/VIAL

N012142 003

Apr CRLD

&gt;D&gt;

AP

1GM/VIAL

N012142 004 Aug 30, 1982 Apr CRLD

&gt;A&gt;

+

1GM/VIAL

N012142 004 Aug 30, 1982 Apr CRLD

&gt;D&gt;

AP

2GM/VIAL

N012142 005 Aug 30, 1982 Apr CRLD

		INJECTABLE; INJECTION							
		CYTOXAN							
>A>	AP	+	BAXTER HLTHCARE	2GM/VIAL	N012142	005	Aug 30, 1982	Apr	CRLD
		<u>CYTARABINE</u>							
		INJECTABLE; INJECTION							
		CYTARABINE							
	AP		ONCO THERAPIES LTD	100MG/ML	A201784	001	Jan 30, 2012	Jan	NEWA
		<u>DACTINOMYCIN</u>							
		INJECTABLE; INJECTION							
		COSMEGEN							
	AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682	001		Mar	CAHN
		<u>DARUNAVIR ETHANOLATE</u>							
		SUSPENSION; ORAL							
		PREZISTA							
		+	JANSSEN PRODS	EQ 100MG BASE/ML	N202895	001	Dec 16, 2011	Feb	CAHN
		TABLET; ORAL							
		PREZISTA							
		JANSSEN PRODS		EQ 75MG BASE	N021976	004	Dec 18, 2008	Feb	CAHN
				EQ 150MG BASE	N021976	005	Dec 18, 2008	Feb	CAHN
		@		EQ 300MG BASE	N021976	001	Jun 23, 2006	Feb	CAHN
				EQ 400MG BASE	N021976	003	Oct 21, 2008	Feb	CAHN
		+		EQ 600MG BASE	N021976	002	Feb 25, 2008	Feb	CAHN
		<u>DESLORATADINE</u>							
		TABLET; ORAL							
		DESLORATADINE							
>A>	AB		BELCHER PHARMS	5MG	A078355	001	Apr 19, 2012	Apr	NEWA
	AB		MYLAN PHARMS INC	5MG	A078351	001	Feb 10, 2012	Jan	NEWA
		<u>DESMOPRESSIN ACETATE</u>							
		SOLUTION; NASAL							
		DDAVP							
	AB	+	SANOFI AVENTIS US	0.01%	N017922	001		Mar	CFTG
		DESMOPRESSIN ACETATE							
	AB		SUN PHARM INDS	0.01%	A077212	001	Apr 12, 2012	Mar	NEWA
		<u>DESOGESTREL; ETHINYL ESTRADIOL</u>							
		TABLET; ORAL-28							
		VIORELE							
	AB		GLENMARK GENERICS	.15MG,N/A; 0.02MG,0.01MG	A091346	001	Apr 02, 2012	Mar	NEWA
		<u>DESONIDE</u>							
		LOTION; TOPICAL							
		DESONIDE							
	AB		FOUGERA PHARMS	0.05%	A075860	001	Mar 19, 2002	Jan	CAHN
		OINTMENT; TOPICAL							
		DESONIDE							
	AB		FOUGERA PHARMS	0.05%	A075751	001	Mar 12, 2001	Jan	CAHN
		<u>DESOXIMETASONE</u>							
		CREAM; TOPICAL							
		DESOXIMETASONE							
	AB		FOUGERA PHARMS	0.25%	A078369	001	Jun 29, 2010	Jan	CAHN

CREAM; TOPICALDESOXIMETASONE

>D>	AB	+	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CTNA
>D>	AB			0.25%	A073193	001	Nov 30, 1990	Apr	CTNA
>A>			TOPICORT						
>A>		+	TARO	0.05%	A073210	001	Nov 30, 1990	Apr	CTNA
>A>		+		0.25%	A073193	001	Nov 30, 1990	Apr	CTNA
>D>	AB	+	TARO PHARMS NORTH	0.25%	N017856	001		Apr	DISC
>A>		@		0.25%	N017856	001		Apr	DISC
>D>			TOPICORT LP						
>D>	AB		TARO PHARMS NORTH	0.05%	N018309	001		Apr	DISC
>A>		@		0.05%	N018309	001		Apr	DISC

GEL; TOPICALDESOXIMETASONE

>D>	AB		TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CTNA
>A>			TOPICORT						
>A>	AB	+	TARO	0.05%	A074904	001	Jul 14, 1998	Apr	CTNA
>D>	AB	+	TARO PHARMS NORTH	0.05%	N018586	001	Mar 29, 1982	Apr	DISC
>A>		@		0.05%	N018586	001	Mar 29, 1982	Apr	DISC

OINTMENT; TOPICALDESOXIMETASONE

>D>	AB	+	TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA
	AB	+		0.25%	A074286	001	Jun 07, 1996	Mar	CRLD
>A>			TOPICORT						
>A>		+	TARO	0.25%	A074286	001	Jun 07, 1996	Apr	CTNA
		@	TARO PHARMS NORTH	0.25%	N018763	001	Sep 30, 1983	Mar	DISC

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTIONDEXAMETHASONE SODIUM PHOSPHATE

AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572	001	Apr 22, 2005	Feb	CRLD
----	---	----------------	----------------------	---------	-----	--------------	-----	------

DIAZEPAMINJECTABLE; INJECTIONDIAZEPAM

>D>	AP		HOSPIRA	5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC
>A>		@		5MG/ML	A071584	001	Oct 13, 1987	Apr	DISC

DIFLORASONE DIACETATECREAM; TOPICALDIFLORASONE DIACETATE

BX	+	FOUGERA PHARMS	0.05%	A076263	001	Dec 20, 2002	Jan	CAHN
AB1	+		0.05%	A075187	001	Mar 30, 1998	Jan	CAHN

OINTMENT; TOPICALDIFLORASONE DIACETATE

AB		FOUGERA PHARMS	0.05%	A075374	001	Apr 27, 1999	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

DIFLUNISALTABLET; ORALDIFLUNISAL

AB		EMCURE PHARMS USA	500MG	A202845	001	Mar 08, 2012	Feb	NEWA
AB	+	TEVA	500MG	A073673	001	Jul 31, 1992	Feb	CTEC

DILTIAZEM HYDROCHLORIDE

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ TEVA PARENTERAL	50MG/ML	A074894 001	Aug 26, 1997	Jan	DISC
-------------------	---------	-------------	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BENADRYL

@ MCNEIL CONS	50MG/ML	N006146 002		Mar	DISC
---------------	---------	-------------	--	-----	------

BENADRYL PRESERVATIVE FREE

@ MCNEIL CONS	50MG/ML	N009486 001		Mar	DISC
---------------	---------	-------------	--	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

>D> AP	BAXTER HLTHCARE	50MG/ML	A080817 002	Apr	CRLD
--------	-----------------	---------	-------------	-----	------

>A> AP	+	50MG/ML	A080817 002	Apr	CRLD
--------	---	---------	-------------	-----	------

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

@ TEVA PARENTERAL	5MG/ML	A074952 001	Nov 26, 1997	Jan	DISC
-------------------	--------	-------------	--------------	-----	------

TABLET; ORAL

DIPYRIDAMOLE

AB	PROSAM LABS	25MG	A040542 001	Apr 21, 2006	Feb CAHN
----	-------------	------	-------------	--------------	----------

AB		50MG	A040542 002	Apr 21, 2006	Feb CAHN
----	--	------	-------------	--------------	----------

AB		75MG	A040542 003	Apr 21, 2006	Feb CAHN
----	--	------	-------------	--------------	----------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB	DR REDDYS LABS LTD	EQ 250MG VALPROIC ACID	A090161 001	Mar 15, 2012	Feb NEWA
----	--------------------	------------------------	-------------	--------------	----------

AB	REDDYS	EQ 500MG VALPROIC ACID	A090070 001	Mar 12, 2012	Feb NEWA
----	--------	------------------------	-------------	--------------	----------

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

>A> AP	ACCORD HLTHCARE	20MG/ML (20MG/ML)	N201195 003	Apr 20, 2012	Apr NEWA
--------	-----------------	-------------------	-------------	--------------	----------

AP		20MG/0.5ML (40MG/ML)	N201195 001	Jun 08, 2011	Jan CTEC
----	--	----------------------	-------------	--------------	----------

>A> AP		80MG/4ML (20MG/ML)	N201195 004	Apr 20, 2012	Apr NEWA
--------	--	--------------------	-------------	--------------	----------

AP		80MG/2ML (40MG/ML)	N201195 002	Jun 08, 2011	Jan CTEC
----	--	--------------------	-------------	--------------	----------

>A>		160MG/8ML (20MG/ML)	N201195 005	Apr 20, 2012	Apr NEWA
-----	--	---------------------	-------------	--------------	----------

AP	APOTEX INC	20MG/0.5ML (40MG/ML)	N022312 001	Jan 11, 2012	Jan NEWA
----	------------	----------------------	-------------	--------------	----------

AP		80MG/2ML (40MG/ML)	N022312 002	Jan 11, 2012	Jan NEWA
----	--	--------------------	-------------	--------------	----------

TAXOTERE

>D>	+	SANOFI AVENTIS US	20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr CTEC
-----	---	-------------------	-------------------	-------------	--------------	----------

>A> AP	+		20MG/ML (20MG/ML)	N020449 003	Aug 03, 2010	Apr CTEC
--------	---	--	-------------------	-------------	--------------	----------

>D>	+		80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr CTEC
-----	---	--	--------------------	-------------	--------------	----------

>A> AP	+		80MG/4ML (20MG/ML)	N020449 004	Aug 02, 2010	Apr CTEC
--------	---	--	--------------------	-------------	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+	MERCK SHARP DOHME	EQ 2% BASE;EQ 0.5% BASE	N202667 001	Feb 01, 2012	Feb NEWA
---	-------------------	-------------------------	-------------	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@	NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@		EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@		EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@		EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+	FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
---	----------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

@	SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
@		EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC

TABLET; ORAL

DOXYCYCLINE

@	SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
@		EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
@		EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

TABLET; ORAL

DOXYCYCLINE HYCLATE

>D>	@	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
>A>	AB		EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
----	---	--------------	---------------	-------------	--------------	-----	------

DOXYCYCLINE HYCLATE

AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA
----	--	------------------	---------------	-------------	--------------	-----	------

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

		BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
--	--	----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

>A>	<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE</u>						
>A>	TABLET; ORAL						
>A>	COMPLERA						
>A>	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123	001	Aug 10, 2011	Apr CAIN
>D>	<u>EMTRICITABINE; RILPIVIRINE; TENOFOVIR DISOPROXIL FUMARATE</u>						
>D>	TABLET; ORAL						
>D>	COMPLERA						
>D>	+	GILEAD SCIENCES INC	200MG;25MG;300MG	N202123	001	Aug 10, 2011	Apr CAIN
	<u>ENALAPRIL MALEATE</u>						
	TABLET; ORAL						
	ENALAPRIL MALEATE						
	@	SANDOZ INC	2.5MG	A075621	001	Aug 22, 2000	Feb DISC
	@		2.5MG	A075496	001	Aug 22, 2000	Jan DISC
	@		5MG	A075621	002	Aug 22, 2000	Feb DISC
	@		5MG	A075496	002	Aug 22, 2000	Jan DISC
	@		10MG	A075621	003	Aug 22, 2000	Feb DISC
	@		10MG	A075459	001	Aug 22, 2000	Jan DISC
	@		20MG	A075621	004	Aug 22, 2000	Feb DISC
	@		20MG	A075459	002	Aug 22, 2000	Jan DISC
	<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>						
	TABLET; ORAL						
	ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE						
	@	SANDOZ INC	5MG;12.5MG	A076116	001	Sep 19, 2001	Mar DISC
	@		10MG;25MG	A076116	002	Sep 19, 2001	Mar DISC
	<u>EPINASTINE HYDROCHLORIDE</u>						
	SOLUTION/DROPS; OPHTHALMIC						
	EPINASTINE HYDROCHLORIDE						
AT		LUITPOLD	0.05%	A090951	001	Oct 31, 2011	Mar CAHN
	<u>EPINEPHRINE</u>						
	INJECTABLE; IM-SC						
	ADRENACLICK						
BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	003	Nov 25, 2009	Mar CAHN
BX	+		EQ 0.3MG /DELIVERY	N020800	004	Nov 25, 2009	Mar CAHN
	TWINJECT 0.15						
BX	+	COREPHARMA	EQ 0.15MG /DELIVERY	N020800	002	May 28, 2004	Mar CAHN
	TWINJECT 0.3						
BX	+	COREPHARMA	EQ 0.3MG /DELIVERY	N020800	001	May 30, 2003	Mar CAHN
	<u>EPIRUBICIN HYDROCHLORIDE</u>						
	INJECTABLE; INJECTION						
	EPIRUBICIN HYDROCHLORIDE						
AP		CIPLA LTD	50MG/25ML (2MG/ML)	A065361	001	Oct 22, 2007	Mar CAHN
AP			200MG/100ML (2MG/ML)	A065361	002	Oct 22, 2007	Mar CAHN
AP		HISUN PHARM HANGZHOU	50MG/25ML (2MG/ML)	A090075	001	Mar 25, 2010	Mar CAHN
AP			200MG/100ML (2MG/ML)	A090075	002	Mar 25, 2010	Mar CAHN
AP		ONCO THERAPIES LTD	50MG/25ML (2MG/ML)	A091599	001	Mar 12, 2012	Mar NEWA
AP			200MG/100ML (2MG/ML)	A091599	002	Mar 12, 2012	Mar NEWA

ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN

AT	FOUGERA PHARMS	2%	A064184	001	Sep 30, 1997	Jan	CAHN
----	----------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL

C-SOLVE-2

AT	FOUGERA PHARMS	2%	A062468	001	Jul 03, 1985	Jan	CMFD
----	----------------	----	---------	-----	--------------	-----	------

SWAB; TOPICAL

ERYCETTE

>A>	@ JOHNSON AND JOHNSON	2%	N050594	001	Feb 15, 1985	Apr	CAHN
-----	-----------------------	----	---------	-----	--------------	-----	------

>D>	@ ORTHO JANSSEN	2%	N050594	001	Feb 15, 1985	Apr	CAHN
-----	-----------------	----	---------	-----	--------------	-----	------

ERYTHROMYCIN

AT	+ FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	Jan	CAHN
----	------------------	----	---------	-----	--------------	-----	------

ESCITALOPRAM OXALATE

SOLUTION; ORAL

ESCITALOPRAM OXALATE

AA	AMNEAL PHARMS	EQ 5MG BASE/5ML	A202227	001	Mar 14, 2012	Feb	NEWA
----	---------------	-----------------	---------	-----	--------------	-----	------

AA	AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML	A079062	001	Apr 02, 2012	Mar	NEWA
----	----------------------	-----------------	---------	-----	--------------	-----	------

>A>	AA	TARO	EQ 5MG BASE/5ML	A079121	001	May 03, 2012	Apr	NEWA
-----	----	------	-----------------	---------	-----	--------------	-----	------

LEXAPRO

AA	+ FOREST LABS	EQ 5MG BASE/5ML	N021365	001	Nov 27, 2002	Feb	CFTG
----	---------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	IVAX SUB TEVA PHARMS	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb	NEWA
----	----------------------	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb	NEWA
----	--	--------------	---------	-----	--------------	-----	------

AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb	NEWA
----	--	--------------	---------	-----	--------------	-----	------

LEXAPRO

AB	FOREST LABS	EQ 5MG BASE	N021323	001	Aug 14, 2002	Feb	CFTG
----	-------------	-------------	---------	-----	--------------	-----	------

AB		EQ 10MG BASE	N021323	002	Aug 14, 2002	Feb	CFTG
----	--	--------------	---------	-----	--------------	-----	------

AB	+	EQ 20MG BASE	N021323	003	Aug 14, 2002	Feb	CFTG
----	---	--------------	---------	-----	--------------	-----	------

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	TEVA PHARMS USA	0.5MG;0.1MG	A200747	001	Mar 08, 2012	Feb	NEWA
----	-----------------	-------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL-28

FALMINA

AB1	NOVAST LABS LTD	0.02MG;0.1MG	A090721	001	Mar 28, 2012	Mar	NEWA
-----	-----------------	--------------	---------	-----	--------------	-----	------

MARLISSA

AB	GLENMARK GENERICS	0.03MG;0.15MG	A091452	001	Feb 29, 2012	Feb	NEWA
----	-------------------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB	GLENMARK GENERICS	0.035MG;1MG	A091634	001	Jan 19, 2012	Jan	NEWA
----	-------------------	-------------	---------	-----	--------------	-----	------

ALYACEN 7/7/7

AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG	A091636	001	Jan 19, 2012	Jan	NEWA
----	-------------------	--	---------	-----	--------------	-----	------

WERA

AB	NOVAST LABS LTD	0.035MG;0.5MG	A091204	001	Mar 27, 2012	Mar	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538	001	Apr 05, 2012	Mar	NEWA
----	-------------------	----------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105	001	Mar 28, 2012	Mar	NEWA
----	-----------------	--------------	---------	-----	--------------	-----	------

ETODOLAC

TABLET; ORAL

ETODOLAC

AB	PROSAM LABS	400MG	A074819	001	Feb 28, 1997	Feb	CMFD
AB		500MG	A074819	002	Apr 28, 1998	Feb	CMFD

ETOPOSIDE

CAPSULE; ORAL

VEPESID

@ CORDEN PHARMA

50MG

N019557 001 Dec 30, 1986 Feb CAHN

@

100MG

N019557 002 Dec 30, 1986 Feb CAHN

INJECTABLE; INJECTION

ETOPOSIDE

AP	+	APP PHARMS LLC	20MG/ML	A074983	001	Sep 30, 1998	Mar	CRLD
----	---	----------------	---------	---------	-----	--------------	-----	------

AP		BEDFORD	20MG/ML	A074290	001	Jul 17, 1995	Mar	CRLD
----	--	---------	---------	---------	-----	--------------	-----	------

VEPESID

@ CORDEN PHARMA

20MG/ML

N018768 001 Nov 10, 1983 Feb CAHN

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D

25MG

N022187 003 Mar 26, 2012 Mar NEWA

100MG

N022187 001 Jan 18, 2008 Feb CAHN

+

200MG

N022187 002 Dec 22, 2010 Feb CAHN

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS

7.5MG

N022334 004 Mar 30, 2012 Apr NEWA

&gt;A&gt;

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+

AMYLIN

2MG/VIAL

N022200 001 Jan 27, 2012 Jan NEWA

EZETIMIBE

TABLET; ORAL

ZETIA

+

MSD INTL GMBH

10MG

N021445 001 Oct 25, 2002 Feb CAHN

+

MSP SINGAPORE

10MG

N021445 001 Oct 25, 2002 Jan CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL

10MG;10MG

N021687 001 Jul 23, 2004 Jan CAHN



## TABLET; ORAL

## VYTORIN

	MSD INTL	10MG;20MG	N021687 002	Jul 23, 2004	Jan	CAHN
		10MG;40MG	N021687 003	Jul 23, 2004	Jan	CAHN
+		10MG;80MG	N021687 004	Jul 23, 2004	Jan	CAHN

FAMCICLOVIR

## TABLET; ORAL

## FAMCICLOVIR

AB	MACLEODS PHARMS LTD	125MG	A201022 001	Jan 12, 2012	Jan	NEWA
AB		250MG	A201022 002	Jan 12, 2012	Jan	NEWA
AB		500MG	A201022 003	Jan 12, 2012	Jan	NEWA

FAMOTIDINE

## TABLET; ORAL

## PEPCID

AB	MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
AB	+	40MG	N019462 002	Oct 15, 1986	Jan	CAHN

## TABLET, ORALLY DISINTEGRATING; ORAL

## FLUXID

	@ UCB INC	20MG	N021712 001	Sep 24, 2004	Jan	CAHN
	@	40MG	N021712 002	Sep 24, 2004	Jan	CAHN

FEBUXOSTAT

## TABLET; ORAL

## ULORIC

>D>	TAKEDA PHARMS	40MG	N021856 001	Feb 13, 2009	Apr	CAHN
>D>	+	80MG	N021856 002	Feb 13, 2009	Apr	CAHN
>A>	TAKEDA PHARMS USA	40MG	N021856 001	Feb 13, 2009	Apr	CAHN
>A>	+	80MG	N021856 002	Feb 13, 2009	Apr	CAHN

FENOFIBRATE

## CAPSULE; ORAL

## ANTARA (MICRONIZED)

AB	LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Feb	CFTG
AB	+	130MG	N021695 003	Nov 30, 2004	Feb	CFTG

## FENOFIBRATE (MICRONIZED)

AB	DR REDDYS LABS SA	43MG	A090859 001	Mar 01, 2012	Feb	NEWA
AB		130MG	A090859 002	Mar 01, 2012	Feb	NEWA

## TABLET; ORAL

## FENOFIBRATE

AB	+	IMPAX LABS	160MG	A076509 002	Mar 26, 2008	Mar	CRLD
		@ TEVA	54MG	A076433 001	May 13, 2005	Mar	DISC
		@	160MG	A076433 002	May 13, 2005	Mar	DISC
AB	VALEANT INTL	48MG	A090715 001	Apr 05, 2012	Mar	NEWA	
AB		145MG	A090715 002	Apr 05, 2012	Mar	NEWA	

FENTANYL

## SPRAY; SUBLINGUAL

## SUBSYS

	INSYS THERAP	0.1MG	N202788 001	Jan 04, 2012	Mar	CPOT
		0.1MCG	N202788 001	Jan 04, 2012	Jan	NEWA
		0.2MG	N202788 002	Jan 04, 2012	Mar	CPOT
		0.2MCG	N202788 002	Jan 04, 2012	Jan	NEWA
+		0.4MG	N202788 003	Jan 04, 2012	Mar	CPOT
+		0.4MCG	N202788 003	Jan 04, 2012	Jan	NEWA

## SPRAY; SUBLINGUAL

## SUBSYS

INSYS THERAP	0.6MG	N202788 004	Jan 04, 2012	Mar	CPOT
	0.6MCG	N202788 004	Jan 04, 2012	Jan	NEWA
	0.8MG	N202788 005	Jan 04, 2012	Mar	CPOT
	0.8MCG	N202788 005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

## SPRAY, METERED; NASAL

## LAZANDA

ARCHIMEDES	EQ 0.1MG BASE	N022569 001	Jun 30, 2011	Jan	CPOT
+	EQ 0.4MG BASE	N022569 002	Jun 30, 2011	Jan	CPOT

## TROCHE/LOZENGE; TRANSMUCOSAL

## FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312 001	Oct 30, 2009	Feb	CAHN
AB		EQ 0.4MG BASE	A077312 002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312 003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312 004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312 005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312 006	Oct 30, 2009	Feb	CAHN

>A> FLORBETAPIR F-18

## &gt;A&gt; SOLUTION; INTRAVENOUS

## &gt;A&gt; AMYVID

>A>	+	AVID RADIOPHARMS INC	10-30ML (13.5-51MCI/ML)	N202008 002	Apr 06, 2012	Apr	NEWA
>A>	+		10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Apr	NEWA
>A>	+		10ML (13.5-51MCI/ML)	N202008 001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLE

## INJECTABLE; INJECTION

## FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012	Jan	NEWA

## FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA

## TABLET; ORAL

## FLUCONAZOLE

	@ PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC	
	@	100MG	A076424 002	Jul 29, 2004	Feb	DISC	
	@	150MG	A076424 003	Jul 29, 2004	Feb	DISC	
	@	200MG	A076424 004	Jul 29, 2004	Feb	DISC	
>D>	AB	RANBAXY	50MG	A076386 001	Jul 29, 2004	Apr	DISC
>D>	AB		100MG	A076386 002	Jul 29, 2004	Apr	DISC
>D>	AB		150MG	A076386 003	Jul 29, 2004	Apr	DISC
>D>	AB		200MG	A076386 004	Jul 29, 2004	Apr	DISC
>A>	@	RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004	Apr	DISC
>A>	@		100MG	A076386 002	Jul 29, 2004	Apr	DISC
>A>	@		150MG	A076386 003	Jul 29, 2004	Apr	DISC
>A>	@		200MG	A076386 004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

## INJECTABLE; INJECTION

## FLUDARA

@	GENZYME CORP	50MG/VIAL	N020038 001	Apr 18, 1991	Mar	DISC
---	--------------	-----------	-------------	--------------	-----	------

## INJECTABLE; INJECTION

## FLUDARABINE PHOSPHATE

AP	+	HOSPIRA	50MG/VIAL	A077790	001	Apr 06, 2007	Mar	CRLD
----	---	---------	-----------	---------	-----	--------------	-----	------

FLUMAZENIL

## INJECTABLE; INJECTION

## FLUMAZENIL

@ TEVA PARENTERAL

0.5MG/5ML (0.1MG/ML)

A076589 002 Oct 12, 2004 Jan DISC

@

1MG/10ML (0.1MG/ML)

A076589 001 Oct 12, 2004 Jan DISC

FLUOCINOLONE ACETONIDE

## OIL/DROPS; OTIC

## FLUOCINOLONE ACETONIDE

AT		IDENTI PHARMS INC	0.01%	A091306	001	Oct 17, 2011	Jan	CPOT
----	--	-------------------	-------	---------	-----	--------------	-----	------

FLUOCINONIDE

## CREAM; TOPICAL

## FLUOCINONIDE EMULSIFIED BASE

AB2		FOUGERA PHARMS	0.05%	A076586	001	Jun 23, 2004	Jan	CAHN
-----	--	----------------	-------	---------	-----	--------------	-----	------

## OINTMENT; TOPICAL

## FLUOCINONIDE

AB		FOUGERA PHARMS	0.05%	A074905	001	Aug 26, 1997	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

FLUOROURACIL

## CREAM; TOPICAL

## FLUOROPLEX

+ AQUA PHARMS

1%

N016988 001 Jan CAHN

FLUOXETINE HYDROCHLORIDE

## CAPSULE; ORAL

## PROZAC

>A>	AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936	006	Dec 23, 1992	Apr	CAHN
-----	-----	------------------	--------------	---------	-----	--------------	-----	------

>A>	AB1		EQ 20MG BASE	N018936	001	Dec 29, 1987	Apr	CAHN
-----	-----	--	--------------	---------	-----	--------------	-----	------

>A>	AB	+	EQ 40MG BASE	N018936	003	Jun 15, 1999	Apr	CAHN
-----	----	---	--------------	---------	-----	--------------	-----	------

>A>		@	EQ 60MG BASE	N018936	004	Jun 15, 1999	Apr	CAHN
-----	--	---	--------------	---------	-----	--------------	-----	------

>D>	AB1	LILLY	EQ 10MG BASE	N018936	006	Dec 23, 1992	Apr	CAHN
-----	-----	-------	--------------	---------	-----	--------------	-----	------

>D>	AB1		EQ 20MG BASE	N018936	001	Dec 29, 1987	Apr	CAHN
-----	-----	--	--------------	---------	-----	--------------	-----	------

>D>	AB	+	EQ 40MG BASE	N018936	003	Jun 15, 1999	Apr	CAHN
-----	----	---	--------------	---------	-----	--------------	-----	------

>D>		@	EQ 60MG BASE	N018936	004	Jun 15, 1999	Apr	CAHN
-----	--	---	--------------	---------	-----	--------------	-----	------

## SARAFEM

>A>	AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936	007	Jul 06, 2000	Apr	CAHN
-----	-----	------------------	--------------	---------	-----	--------------	-----	------

>A>	AB2	+	EQ 20MG BASE	N018936	008	Jul 06, 2000	Apr	CAHN
-----	-----	---	--------------	---------	-----	--------------	-----	------

>D>	AB2	LILLY	EQ 10MG BASE	N018936	007	Jul 06, 2000	Apr	CAHN
-----	-----	-------	--------------	---------	-----	--------------	-----	------

>D>	AB2	+	EQ 20MG BASE	N018936	008	Jul 06, 2000	Apr	CAHN
-----	-----	---	--------------	---------	-----	--------------	-----	------

FLURANDRENOLIDE

## CREAM; TOPICAL

## CORDRAN SP

>D>		@ WATSON PHARMS	0.05%	N012806	002		Apr	CMFD
-----	--	-----------------	-------	---------	-----	--	-----	------

>A>			0.05%	N012806	002		Apr	CMFD
-----	--	--	-------	---------	-----	--	-----	------

FLUTAMIDE

## CAPSULE; ORAL

## FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780	001	Sep 19, 2001	Mar	CRLD
----	---	----------------------	-------	---------	-----	--------------	-----	------

AB		SANDOZ INC	125MG	A075818	001	Sep 18, 2001	Mar	CRLD
----	--	------------	-------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB + FOUGERA PHARMS 0.05% N019958 001 Dec 18, 1990 Jan CAHN

FLUTICASONE PROPIONATE

AB FOUGERA PHARMS 0.05% A076451 001 May 14, 2004 Jan CAHN

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB FOUGERA PHARMS 0.005% A076300 001 May 14, 2004 Jan CAHN

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB MYLAN PHARMS INC EQ 20MG BASE A090595 001 Apr 11, 2012 Mar NEWA

AB EQ 40MG BASE A090595 002 Apr 11, 2012 Mar NEWA

LESCOL

AB NOVARTIS EQ 20MG BASE N020261 001 Dec 31, 1993 Mar CFTG

AB + EQ 40MG BASE N020261 002 Dec 31, 1993 Mar CFTG

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

&gt;D&gt; AB RANBAXY 10MG A076580 001 Apr 23, 2004 Apr DISC

&gt;D&gt; AB 20MG A076580 002 Apr 23, 2004 Apr DISC

&gt;D&gt; AB 40MG A076580 003 Apr 23, 2004 Apr DISC

&gt;A&gt; @ RANBAXY LABS LTD 10MG A076580 001 Apr 23, 2004 Apr DISC

&gt;A&gt; @ 20MG A076580 002 Apr 23, 2004 Apr DISC

&gt;A&gt; @ 40MG A076580 003 Apr 23, 2004 Apr DISC

MONOPRIL

@ BRISTOL MYERS SQUIBB 10MG N019915 002 May 16, 1991 Mar DISC

@ 20MG N019915 003 May 16, 1991 Mar DISC

@ 40MG N019915 004 Mar 28, 1995 Mar DISC

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

@ TEVA PARENTERAL EQ 50MG PHENYTOIN NA/ML A076886 001 Aug 06, 2007 Mar DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA AMNEAL PHARMS 250MG/5ML A202024 001 Mar 23, 2012 Mar NEWA

&gt;A&gt; AA KIEL 250MG/5ML A076403 001 May 01, 2012 Apr NEWA

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

&gt;D&gt; RANBAXY 250MG A076457 001 Jun 27, 2003 Apr DISC

&gt;D&gt; + 500MG A076457 002 Jun 27, 2003 Apr DISC

&gt;A&gt; @ RANBAXY LABS LTD 250MG A076457 001 Jun 27, 2003 Apr DISC

&gt;A&gt; @ 500MG A076457 002 Jun 27, 2003 Apr DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

>D>		GEMCITABINE							
>D>	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Apr	CTNA	
>D>	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Apr	CTNA	
>D>	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Apr	CTNA	
>A>		GEMCITABINE HYDROCHLORIDE							
>A>	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795	001	Aug 04, 2011	Apr	CTNA	
>A>	+		1GM/26.3ML (38MG/ML)	N200795	002	Aug 04, 2011	Apr	CTNA	
>A>	+		2GM/52.6ML (38MG/ML)	N200795	003	Aug 04, 2011	Apr	CTNA	

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

>D>	AB	RANBAXY	1MG	A076875	001	Oct 06, 2005	Apr	DISC	
>D>	AB		2MG	A076875	002	Oct 06, 2005	Apr	DISC	
>D>	AB		4MG	A076875	003	Oct 06, 2005	Apr	DISC	
>D>	AB		8MG	A076875	004	Oct 06, 2005	Apr	DISC	
>A>		@ RANBAXY LABS LTD	1MG	A076875	001	Oct 06, 2005	Apr	DISC	
>A>		@	2MG	A076875	002	Oct 06, 2005	Apr	DISC	
>A>		@	4MG	A076875	003	Oct 06, 2005	Apr	DISC	
>A>		@	8MG	A076875	004	Oct 06, 2005	Apr	DISC	

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA		NEXGEN PHARMA	1.5MG	A091522	001	Mar 12, 2012	Feb	NEWA	
----	--	---------------	-------	---------	-----	--------------	-----	------	--

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP		CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262	001	Dec 31, 2007	Mar	CAHN	
AP			EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258	001	Jun 30, 2008	Mar	CAHN	
AP			EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258	002	Jun 30, 2008	Mar	CAHN	
>D>	AP	APP PHARMS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096	001	Jun 30, 2008	Apr	CRLD	
>A>	AP	+	APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096	001	Jun 30, 2008	Apr	CRLD
>D>	AP	+	TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	Apr	DISC
>A>		@	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165	001	Dec 31, 2007	Apr	DISC	

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

AB	+	VALEANT PHARM NORTH	125MG/5ML	A062483	001	Jan 26, 1984	Feb	CAHN	
----	---	---------------------	-----------	---------	-----	--------------	-----	------	--

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A077001	001	Dec 16, 2004	Jan	CAHN	
----	--	----------------	-------	---------	-----	--------------	-----	------	--

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB		FOUGERA PHARMS	0.05%	A076903	001	Dec 16, 2004	Jan	CAHN	
----	--	----------------	-------	---------	-----	--------------	-----	------	--

HEPARIN SODIUM

## INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 2,000 UNITS/100ML N018814 002 Jul 09, 1985 Mar DISC

HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 4,000 UNITS/100ML N018814 001 Oct 31, 1983 Mar DISC

HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5,000 UNITS/100ML N018814 003 Jul 09, 1985 Mar DISC

@ 10,000 UNITS/100ML N018814 004 Jul 02, 1987 Mar DISC

HYDROCHLOROTHIAZIDE

## CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB LANNETT HOLDINGS INC 12.5MG A091662 001 Jan 27, 2012 Jan NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

## TABLET; ORAL

AVALIDE

AB + SANOFI AVENTIS 12.5MG;150MG N020758 002 Sep 30, 1997 Mar CFTG

AB + 12.5MG;300MG N020758 003 Aug 31, 1998 Mar CFTG

+ 12.5MG;300MG N020758 003 Aug 31, 1998 Feb CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB TEVA 12.5MG;150MG A077369 001 Mar 30, 2012 Mar NEWA

AB 12.5MG;300MG A077369 002 Mar 30, 2012 Mar NEWA

&gt;D&gt; 25MG;300MG A077369 003 Mar 30, 2012 Apr DISC

&gt;A&gt; @ 25MG;300MG A077369 003 Mar 30, 2012 Apr DISC

25MG;300MG A077369 003 Mar 30, 2012 Mar NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

## TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB ALEMBIC LTD 12.5MG;50MG A091617 001 Feb 17, 2012 Feb NEWA

AB 12.5MG;100MG A091617 002 Feb 17, 2012 Feb NEWA

AB 25MG;100MG A091617 003 Feb 17, 2012 Feb NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

## TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

ASTRAZENECA 12.5MG;EQ 25MG TARTRATE N021956 001 Aug 28, 2006 Jan CMFD

12.5MG;EQ 50MG TARTRATE N021956 002 Aug 28, 2006 Jan CMFD

&gt;D&gt; 12.5MG;EQ 100MG TARTRATE N021956 003 Aug 28, 2006 Apr CRLD

&gt;A&gt; + 12.5MG;EQ 100MG TARTRATE N021956 003 Aug 28, 2006 Apr CRLD

12.5MG;EQ 100MG TARTRATE N021956 003 Aug 28, 2006 Jan CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

## TABLET; ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB MYLAN 50MG;100MG A076792 003 Aug 20, 2004 Jan CTEC

AB SUN PHARM INDS 25MG;50MG A090654 001 Jan 19, 2012 Jan NEWA

AB 25MG;100MG A090654 002 Jan 19, 2012 Jan NEWA

AB 50MG;100MG A090654 003 Jan 19, 2012 Jan NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	PADDOCK LLC	12.5MG;7.5MG	A090096	001	Sep 25, 2008	Jan	DISC
@		12.5MG;15MG	A090096	002	Sep 25, 2008	Jan	DISC
@		25MG;15MG	A090096	003	Sep 25, 2008	Jan	DISC

HYDROCORTISONE

LOTION; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	2.5%	A040351	001	Jul 25, 2000	Jan	CAHN
----	---	----------------	------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE

AT	+	FOUGERA PHARMS	1%	A080692	001		Jan	CAHN
----	---	----------------	----	---------	-----	--	-----	------

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT		FOUGERA PHARMS	1%;10%	A080505	001		Jan	CAHN
----	--	----------------	--------	---------	-----	--	-----	------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB	+	TARO	0.2%	A075042	001	Aug 25, 1998	Mar	CRLD
----	---	------	------	---------	-----	--------------	-----	------

WESTCORT

@ RANBAXY 0.2%

N017950	001		Mar	DISC
---------	-----	--	-----	------

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB		FOUGERA PHARMS	0.2%	A075085	001	Jul 31, 2001	Jan	CAHN
----	--	----------------	------	---------	-----	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+	SHIRE LLC	50MG	N011949	001		Jan	CAHN
----	---	-----------	------	---------	-----	--	-----	------

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@	STI PHARMA LLC	10MG/5ML	A086880	001		Feb	CAHN
---	----------------	----------	---------	-----	--	-----	------

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB	+	HOFFMANN LA ROCHE	EQ 150MG BASE	N021455	002	Mar 24, 2005	Mar	CFTG
----	---	-------------------	---------------	---------	-----	--------------	-----	------

IBANDRONATE SODIUM

AB		APOTEX INC	EQ 150MG BASE	A078948	001	Mar 19, 2012	Mar	NEWA
----	--	------------	---------------	---------	-----	--------------	-----	------

>A>	AB	DR REDDYS LABS LTD	EQ 150MG BASE	A078997	001	Apr 30, 2012	Apr	NEWA
-----	----	--------------------	---------------	---------	-----	--------------	-----	------

AB		MYLAN PHARMS INC	EQ 150MG BASE	A078995	001	Mar 19, 2012	Mar	NEWA
----	--	------------------	---------------	---------	-----	--------------	-----	------

AB		ORCHID HLTHCARE	EQ 150MG BASE	A078998	001	Mar 19, 2012	Mar	NEWA
----	--	-----------------	---------------	---------	-----	--------------	-----	------

AB		WATSON LABS INC	EQ 150MG BASE	A079003	001	Mar 20, 2012	Mar	NEWA
----	--	-----------------	---------------	---------	-----	--------------	-----	------

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS  
NEOPROFEN

+	LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
---	--------------	---------------------------------------	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION  
IDARUBICIN HYDROCHLORIDE

@	TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
@		10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
@		20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL  
IMIPRAMINE HYDROCHLORIDE

AB	PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
AB		25MG	A040752 001	Feb 28, 2008	Feb	CMFD
AB		50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL  
IMIQUIMOD

AB	APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB	FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB	GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDOMETHACIN SODIUM

INJECTABLE; INJECTION  
INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
----	---	--------------	------------------	-------------	--------------	-----	------

INGENOL MEBUTATE

GEL; TOPICAL  
PICATO

	LEO PHARMA AS	0.015%	N202833 001	Jan 23, 2012	Jan	NEWA
+		0.05%	N202833 002	Jan 23, 2012	Jan	NEWA

IRBESARTAN

TABLET; ORAL  
AVAPRO

AB	SANOFI AVENTIS US	75MG	N020757 001	Sep 30, 1997	Mar	CFTG
AB		150MG	N020757 002	Sep 30, 1997	Mar	CFTG
AB	+	300MG	N020757 003	Sep 30, 1997	Mar	CFTG
	IRBESARTAN					
AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA



INJECTABLE; INJECTIONIRINOTECAN HYDROCHLORIDE

AP	EMCURE PHARMS LTD	100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
	@ TEVA PARENTERAL	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOSORBIDE MONONITRATE

## TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

	@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC
--	-----------------	------	-------------	--------------	-----	------

ISOTRETINOIN

## CAPSULE; ORAL

MYORISAN

AB	DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB		20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB		40MG	A076485 003	Jan 19, 2012	Jan	NEWA

IVACAFTOR

## TABLET; ORAL

KALYDECO

+	VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
---	---------------	-------	-------------	--------------	-----	------

IVERMECTIN

## LOTION; TOPICAL

SKLICE

+	SANOFI PASTEUR	0.5%	N202736 001	Feb 07, 2012	Feb	NEWA
---	----------------	------	-------------	--------------	-----	------

KETOCONAZOLE

## CREAM; TOPICAL

KETOCONAZOLE

AB	FOUGERA PHARMS	2%	A076294 001	Apr 28, 2004	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

LABETALOL HYDROCHLORIDE

## INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	GLAND PHARMA LTD	5MG/ML	A090699 001	Apr 03, 2012	Mar	NEWA
----	------------------	--------	-------------	--------------	-----	------

LACTULOSE

## SOLUTION; ORAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090503 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

## SOLUTION; ORAL, RECTAL

LACTULOSE

AA	FRESENIUS KABI	10GM/15ML	A090502 001	Jan 25, 2012	Jan	NEWA
----	----------------	-----------	-------------	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

## TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

>A>	AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
>A>	AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

>A>	AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
>A>	AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
>A>	AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
>A>	AB		200MG	A090169 004	May 12, 2012	Apr	NEWA

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

>A>	+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
>A>	+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
>A>	+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
>D>	+	IPSEN PHARMS	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
>D>	+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
>D>	+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

PREVACID

AB		TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+		30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

	@	TEVA PHARMS	15MG	A078730 001	Oct 15, 2010	Mar	DISC
	@		30MG	A078730 002	Oct 15, 2010	Mar	DISC

PREVACID

		TAKEDA PHARMS USA	15MG	N021428 001	Aug 30, 2002	Mar	CTEC
	+		30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

	@	SHIRE LLC	EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
			EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
			EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
	+		EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LETROZOLE

TABLET; ORAL

LETROZOLE

>A>	AB	APOTEX INC	2.5MG	A091303 001	Apr 19, 2012	Apr	NEWA
-----	----	------------	-------	-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

	@	TEVA PARENTERAL	EQ 50MG BASE/VIAL	A081278 001	Sep 28, 1993	Mar	DISC
--	---	-----------------	-------------------	-------------	--------------	-----	------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP		HOSPIRA INC	500MG/ML (100MG/ML)	A202869 001	Apr 06, 2012	Mar	NEWA
AP		PHARMAFORCE	500MG/5ML (100MG/ML)	A202143 001	Jan 31, 2012	Jan	NEWA

## SOLUTION; ORAL

## LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML	A090601	001	Feb 28, 2012	Feb	NEWA
AA	VINTAGE PHARMS	100MG/ML	A090079	001	Apr 11, 2012	Mar	NEWA

## TABLET; ORAL

## LEVETIRACETAM

>A>	AB	WATSON LABS INC	250MG	A078797	002	Jan 15, 2009	Apr	NEWA
>A>	AB		500MG	A078797	003	Jan 15, 2009	Apr	NEWA
>A>	AB		750MG	A078797	004	Jan 15, 2009	Apr	NEWA

LEVOFLOXACIN

## TABLET; ORAL

## LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890	001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890	002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890	003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839	001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839	002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839	003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200	001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200	002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200	003	Jan 30, 2012	Jan	NEWA

LIDOCAINE; PRILOCAINE

## CREAM; TOPICAL

## LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453	001	Aug 18, 2003	Jan	CAHN
----	----------------	-----------	---------	-----	--------------	-----	------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

## TABLET; ORAL

## JENTADUETO

	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281	001	Jan 30, 2012	Jan	NEWA
		2.5MG;850MG	N201281	002	Jan 30, 2012	Jan	NEWA
	+	2.5MG;1GM	N201281	003	Jan 30, 2012	Jan	NEWA

LORAZEPAM

## CONCENTRATE; ORAL

## LORAZEPAM

AA	HI-TECH PHARMA CO	2MG/ML	A200169	001	Jan 30, 2012	Jan	NEWA
----	-------------------	--------	---------	-----	--------------	-----	------

>A> LUCINACTANT

&gt;A&gt; SUSPENSION; INTRATRACHEAL

&gt;A&gt; SURFAXIN

>A>	+	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	Apr	NEWA
-----	---	----------------	-------	---------	-----	--------------	-----	------

LURASIDONE HYDROCHLORIDE

## TABLET; ORAL

## LATUDA

>D>		SUNOVION	40MG	N200603	001	Oct 28, 2010	Apr	CRLD
>D>	+		80MG	N200603	002	Oct 28, 2010	Apr	CRLD
>A>		SUNOVION PHARMS INC	20MG	N200603	003	Dec 07, 2011	Apr	NEWA
>A>	+		40MG	N200603	001	Oct 28, 2010	Apr	CRLD
>A>			80MG	N200603	002	Oct 28, 2010	Apr	CRLD
>A>			120MG	N200603	004	Apr 26, 2012	Apr	NEWA

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA	20GM/500ML (40MG/ML)	N020309 004	Jan 18, 1995	Jan	NEWA
	40GM/1000ML(40MG/ML)	N020309 005	Jan 18, 1995	Jan	NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT	MYLAN PHARMS INC	0.5%	A078743 001	Mar 06, 2009	Feb	CAHN
----	------------------	------	-------------	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

>D>	AB	TEVA PARENTERAL	150MG/ML	A076552 001	Oct 27, 2004	Apr	DISC
>A>		@	150MG/ML	A076552 001	Oct 27, 2004	Apr	DISC

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

		@ ORCHID HLTHCARE	5MG	A090044 001	Mar 12, 2012	Mar	DISC
AB			5MG	A090044 001	Mar 12, 2012	Feb	NEWA
		@	10MG	A090044 002	Mar 12, 2012	Mar	DISC
AB			10MG	A090044 002	Mar 12, 2012	Feb	NEWA
		NAMENDA					
		FOREST LABS	5MG	N021487 001	Oct 16, 2003	Mar	CTEC
AB			5MG	N021487 001	Oct 16, 2003	Feb	CTEC
		+	10MG	N021487 002	Oct 16, 2003	Mar	CTEC
AB		+	10MG	N021487 002	Oct 16, 2003	Feb	CTEC

MESALAMINE

SUPPOSITORY; RECTAL

ROWASA

@	MEDA PHARMS	500MG	N019919 001	Dec 18, 1990	Jan	CAHN
---	-------------	-------	-------------	--------------	-----	------

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP	MYLAN INSTITUTIONAL	100MG/ML	A076488 001	Mar 08, 2012	Feb	NEWA
----	---------------------	----------	-------------	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	MARKSANS PHARMA	500MG	A090888 001	Mar 12, 2012	Feb	NEWA
AB		850MG	A090888 002	Mar 12, 2012	Feb	NEWA
AB		1GM	A090888 003	Mar 12, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1	INVENTIA HLTHCARE	500MG	A201991 001	Jan 18, 2012	Jan	NEWA
-----	-------------------	-------	-------------	--------------	-----	------

## TABLET, EXTENDED RELEASE; ORAL

## METFORMIN HYDROCHLORIDE

>D>	AB	RANBAXY	750MG	A077211	001	Jun 29, 2005	Apr	DISC
>D>	AB1	RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004	Apr	DISC
>A>		@	500MG	A076413	001	Jun 18, 2004	Apr	DISC
>A>		@	750MG	A077211	001	Jun 29, 2005	Apr	DISC

>D> METFORMIN HYDROCHLORIDE; SAXAGLIPTIN

## TABLET, EXTENDED RELEASE; ORAL

## KOMBIGLYZE XR

>D>		BRISTOL MYERS SQUIBB	500MG;5MG	N200678	001	Nov 05, 2010	Apr	CAIN
>D>			1GM;2.5MG	N200678	003	Nov 05, 2010	Apr	CAIN
>D>	+		1GM;5MG	N200678	002	Nov 05, 2010	Apr	CAIN

>A> METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## KOMBIGLYZE XR

>A>		BRISTOL MYERS SQUIBB	500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr	CAIN
>A>			1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr	CAIN
>A>	+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

## TABLET, EXTENDED RELEASE; ORAL

## JANUMET XR

		MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270	001	Feb 02, 2012	Feb	NEWA
			1GM;EQ 50MG BASE	N202270	002	Feb 02, 2012	Feb	NEWA
	+		1GM;EQ 100MG BASE	N202270	003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

## TABLET; ORAL

## METHIMAZOLE

AB		BOCA PHARMA	5MG	A202068	001	Mar 07, 2012	Feb	NEWA
AB			10MG	A202068	002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

## TABLET; ORAL

## METHOCARBAMOL

AA		SOLCO HLTHCARE	500MG	A086989	001		Mar	CMFD
AA			750MG	A086988	001		Mar	CMFD

METHOTREXATE SODIUM

## INJECTABLE; INJECTION

## METHOTREXATE PRESERVATIVE FREE

AP		APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266	001	Feb 26, 1999	Jan	CMFD
AP		PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171	001	Feb 27, 2012	Feb	NEWA

## METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Feb	CTEC
----	---	---------	-------------------------------------	---------	-----	--------------	-----	------

## METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767	001	Apr 30, 2007	Feb	CAHN
AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529	001	Mar 29, 2012	Mar	NEWA
AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529	002	Mar 29, 2012	Mar	NEWA
AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529	003	Mar 29, 2012	Mar	NEWA

## INJECTABLE; INJECTION

## METHOTREXATE SODIUM PRESERVATIVE FREE

AP	ONCO THERAPIES LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHYCLOTHIAZIDE

## TABLET; ORAL

## ENDURON

	@ ABBOTT LABS PHARM	2.5MG	N012524 001		Mar	DISC
	@	5MG	N012524 004		Mar	DISC

## METHYCLOTHIAZIDE

AB	+ MYLAN PHARMS INC	5MG	A087672 001	Aug 17, 1982	Mar	CRLD
----	--------------------	-----	-------------	--------------	-----	------

METHYLDOPATE HYDROCHLORIDE

## INJECTABLE; INJECTION

## METHYLDOPATE HYDROCHLORIDE

	@ TEVA PARENTERAL	50MG/ML	A072974 001	Nov 22, 1991	Mar	DISC
--	-------------------	---------	-------------	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

## TABLET; ORAL

## METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

## INJECTABLE; INJECTION

## METHYLPREDNISOLONE SODIUM SUCCINATE

	@ TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC
--	-------------------	--------------------	-------------	--------------	-----	------

METOCLOPRAMIDE HYDROCHLORIDE

## INJECTABLE; INJECTION

## METOCLOPRAMIDE HYDROCHLORIDE

	@ TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
--	-------------------	----------------	-------------	--------------	-----	------

METRONIDAZOLE

## CREAM; TOPICAL

## METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

## NORITATE

>D>	+ SANOFI AVENTIS US	1%	N020743 001	Sep 26, 1997	Apr	CAHN
-----	---------------------	----	-------------	--------------	-----	------

>A>	+ VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN
-----	----------------	----	-------------	--------------	-----	------

## GEL; TOPICAL

## METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

## LOTION; TOPICAL

## METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

## INJECTABLE; INJECTION

## MIDAZOLAM HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB	SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
AB	+	5MG	N019815 002	Sep 06, 1996	Jan	CAHN
AB		10MG	N019815 003	Mar 20, 2002	Jan	CAHN

MIFEPRISTONE

TABLET; ORAL

KORLYM

+	CORCEPT THERAP	300MG	N202107 001	Feb 17, 2012	Feb	NEWA
---	----------------	-------	-------------	--------------	-----	------

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+	MOBIUS THERAP	0.2MG/VIAL	N022572 001	Feb 07, 2012	Feb	NEWA
---	---------------	------------	-------------	--------------	-----	------

MOMETASONE FUROATE

CREAM; TOPICAL

MOMETASONE FUROATE

AB	FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

MOMETASONE FUROATE

AB	FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

MOMETASONE FUROATE

AB	FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

MORPHINE SULFATE

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

>A>	AB	RANBAXY LABS LTD	15MG	A078761 001	May 11, 2012	Apr	NEWA
>A>	AB		30MG	A078761 002	May 11, 2012	Apr	NEWA
>A>	AB		60MG	A078761 003	May 11, 2012	Apr	NEWA
>A>	AB		100MG	A078761 004	May 11, 2012	Apr	NEWA
>A>	AB		200MG	A078761 005	May 11, 2012	Apr	NEWA

MUPIROCIN

OINTMENT; TOPICAL

MUPIROCIN

AB	FOUGERA PHARMS	2%	A065192 001	Nov 30, 2005	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

NABUMETONE

TABLET; ORAL

NABUMETONE

AB	PROSAM LABS	500MG	A079093 001	Feb 27, 2009	Feb	CMFD
AB		750MG	A079093 002	Feb 27, 2009	Feb	CMFD

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+	MERZ PHARMS	2%	N019599 002	Jan 13, 2012	Jan	NEWA
---	-------------	----	-------------	--------------	-----	------

NALTREXONE HYDROCHLORIDE

TABLET; ORAL

NALTREXONE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	50MG	A090356	001	Feb 24, 2012	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

>A>	AB	ORCHID HLTHCARE	EQ 1MG BASE	A091441	001	Apr 30, 2012	Apr	NEWA
>A>	AB		EQ 2.5MG BASE	A091441	002	Apr 30, 2012	Apr	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

>D>	AB	RANBAXY	75MG;25MG	A076951	001	Mar 30, 2005	Apr	DISC
>A>		@ RANBAXY LABS LTD	75MG;25MG	A076951	001	Mar 30, 2005	Apr	DISC

NITROGLYCERIN

OINTMENT; INTRA-ANAL

RECTIV

	+	APTALIS PHARMA	0.4%	N021359	001	Jun 21, 2011	Jan	CAHN
--	---	----------------	------	---------	-----	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

AXID

@ SMITHKLINE BEECHAM 150MG

N019508 001 Apr 12, 1988 Mar DISC

@ 300MG

N019508 002 Apr 12, 1988 Mar DISC

NIZATIDINE

>D>	AB	MYLAN	150MG	A075934	001	Jul 09, 2002	Apr	DISC
>D>	AB		300MG	A075806	002	Jul 05, 2002	Apr	CRLD
>D>	AB		300MG	A075934	002	Jul 09, 2002	Apr	DISC
>A>		@ MYLAN PHARMS INC	150MG	A075934	001	Jul 09, 2002	Apr	DISC
>A>		@	300MG	A075934	002	Jul 09, 2002	Apr	DISC
>A>	AB	+	300MG	A075806	002	Jul 05, 2002	Apr	CRLD

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP	SINETICA	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Mar	NEWA
----	----------	----------------	---------	-----	--------------	-----	------

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT	FOUGERA PHARMS	100,000 UNITS/GM	A062129	001		Jan	CAHN
----	----------------	------------------	---------	-----	--	-----	------

OINTMENT; TOPICAL

NYSTATIN

AT	+	FOUGERA PHARMS	100,000 UNITS/GM	A062124	002	Sep 23, 1982	Jan	CAHN
----	---	----------------	------------------	---------	-----	--------------	-----	------

OFLOXACIN

TABLET; ORAL

OFLOXACIN

>D>	AB	RANBAXY	200MG	A076220	001	Sep 02, 2003	Apr	DISC
>D>	AB		300MG	A076220	002	Sep 02, 2003	Apr	DISC
>D>	AB		400MG	A076220	003	Sep 02, 2003	Apr	DISC
>A>		@ RANBAXY LABS LTD	200MG	A076220	001	Sep 02, 2003	Apr	DISC



## TABLET; ORAL

## OFLOXACIN

>A>	@ RANBAXY LABS LTD	300MG	A076220 002	Sep 02, 2003	Apr	DISC
>A>	@	400MG	A076220 003	Sep 02, 2003	Apr	DISC

OLANZAPINE

## INJECTABLE; INTRAMUSCULAR

## OLANZAPINE

AP	PHARMAFORCE	10MG/VIAL	A201741 001	Mar 20, 2012	Mar	NEWA
AP	SANDOZ INC	10MG/VIAL	A201588 001	Oct 24, 2011	Mar	CAHN

## TABLET; ORAL

## OLANZAPINE

>A>	AB	APOTEX INC	2.5MG	A090798 001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A090798 002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A090798 003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A090798 004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A090798 005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A090798 006	Apr 23, 2012	Apr	NEWA
>A>	AB	AUROBINDO PHARMA LTD	2.5MG	A202050 001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A202050 002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A202050 003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A202050 004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A202050 005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A202050 006	Apr 23, 2012	Apr	NEWA
>A>	AB	DR REDDYS LABS LTD	2.5MG	A076255 001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A076255 002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A076255 003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A076255 004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A076133 001	Apr 23, 2012	Apr	NEWA
>A>	AB	MYLAN	2.5MG	A076866 001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A076866 002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A076866 003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A076866 004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A076866 005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A076866 006	Apr 23, 2012	Apr	NEWA
>A>	AB	ORCHID HLTHCARE	2.5MG	A202287 001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A202287 002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A202287 003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A202287 004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A202287 005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A202287 006	Apr 23, 2012	Apr	NEWA
>A>	AB	SUN PHARM INDS	2.5MG	A091038 001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A091038 002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A091038 003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A091038 004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A091038 005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A091038 006	Apr 23, 2012	Apr	NEWA
>A>	AB	TORRENT PHARMS LTD	2.5MG	A091434 001	Apr 23, 2012	Apr	NEWA
>A>	AB		5MG	A091434 002	Apr 23, 2012	Apr	NEWA
>A>	AB		7.5MG	A091434 003	Apr 23, 2012	Apr	NEWA
>A>	AB		10MG	A091434 004	Apr 23, 2012	Apr	NEWA
>A>	AB		15MG	A091434 005	Apr 23, 2012	Apr	NEWA
>A>	AB		20MG	A091434 006	Apr 23, 2012	Apr	NEWA

## TABLET, ORALLY DISINTEGRATING; ORAL

## OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
----	---------------	-----	-------------	--------------	-----	------

## TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

OMEPRAZOLE

\*\*\*\*\*; ORAL

OMEPRAZOLE

>A>	AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
>A>	AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+	ROCHE	EQ 6MG BASE/ML	N021246 002	Mar 21, 2011	Jan	CRLD
---	-------	----------------	-------------	--------------	-----	------

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP	SAGENT PHARMS	EQ 1GM BASE/VIAL	A091246 001	Mar 30, 2012	Mar	NEWA
AP		EQ 2GM BASE/VIAL	A091246 002	Mar 30, 2012	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A091245 001	Mar 30, 2012	Mar	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	+	TEVA PHARMS	50MG/10ML (5MG/ML)	N022160 001	Aug 07, 2009	Mar	CRLD
AP	+		100MG/20ML (5MG/ML)	N022160 002	Aug 07, 2009	Mar	CRLD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

>A>	+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
>D>	+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Apr	CAHN
	+		3%	N202513 001	Dec 07, 2011	Feb	CAHN

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS

OXYBUTYNIN CHLORIDE

			5MG	N017577 001		Mar	DISC
AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
AB		MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

+ VISTAPHARM 5MG/5ML N201194 001 Jan 12, 2012 Jan NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

&gt;A&gt; AB MALLINCKRODT INC 5MG A076758 003 Mar 19, 2007 Apr NEWA

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@ TEVA PARENTERAL 10USP UNITS/ML (10USP UNITS/ML) A077453 001 Jan 24, 2008 Jan DISC

@ 100USP UNITS/10ML (10USP UNITS/ML) A077453 002 Jan 24, 2008 Mar DISC

PACLITAXEL

INJECTABLE; INJECTION

TAXOL

@ CORDEN PHARMA 6MG/ML N020262 001 Dec 29, 1992 Mar CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

ARELIA

@ NOVARTIS 30MG/VIAL N020036 001 Oct 31, 1991 Mar DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

ABBOTT LABS 30,000USP UNITS;6,000USP UNITS;19,000USP UNITS N020725 001 Apr 30, 2009 Feb CAHN

60,000USP UNITS;12,000USP UNITS;38,000USP UNITS N020725 002 Apr 30, 2009 Feb CAHN

+ 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS N020725 003 Apr 30, 2009 Feb CAHN

ULTRESA

APTALIS PHARMA US 27,600USP UNITS;13,800USP UNITS;27,600USP UNITS N022222 001 Mar 01, 2012 Mar NEWA

41,400USP UNITS;20,700USP UNITS;41,400USP UNITS N022222 002 Mar 01, 2012 Mar NEWA

+ 46,000USP UNITS;23,000USP UNITS;46,000USP UNITS N022222 003 Mar 01, 2012 Mar NEWA

ZENPEP

&gt;A&gt; APTALIS PHARMA US 16,000USP UNITS;3,000USP UNITS;10,000USP UNITS N022210 005 Jun 15, 2011 Apr NEWA

&gt;D&gt; + 109,000USP UNITS;20,000USP UNITS;68,000USP UNITS N022210 004 Aug 27, 2009 Apr CRLD

&gt;A&gt; 109,000USP UNITS;20,000USP UNITS;68,000USP UNITS N022210 004 Aug 27, 2009 Apr CRLD

&gt;A&gt; + 136,000USP UNITS;25,000USP UNITS;85,000USP UNITS N022210 006 Jul 13, 2011 Apr NEWA

TABLET; ORAL

VIOKACE

APTALIS PHARMA US 39,150USP UNITS;10,440USP UNITS;39,150USP UNITS N022542 001 Mar 01, 2012 Mar NEWA

+ 78,300USP UNITS;20,880USP UNITS;78,300USP UNITS N022542 002 Mar 01, 2012 Mar NEWA

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

>A>	AB	APOTEX INC	EQ 20MG BASE	A090807 001	May 02, 2012	Apr	NEWA
>A>	AB		EQ 40MG BASE	A090807 002	May 02, 2012	Apr	NEWA
	AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012	Jan	NEWA
	AB		EQ 40MG BASE	A200821 002	Feb 16, 2012	Jan	NEWA
>A>	AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr	NEWA
>A>	AB		EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB		ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
AB			EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB			EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB			EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+		AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+			EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+		AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+			EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+			EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+			EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+			EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+			EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+		OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	--	------------	---------	-------------	--	-----	------

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB		XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB			4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+		8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA		LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
----	--	---------	------	-------------	--------------	-----	------

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

		@ SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC
--	--	--------------	------	-------------	--------------	-----	------

## TABLET, ORALLY DISINTEGRATING; ORAL

## SUPRENZA

>D>	+	CITIUS PHARMS	30MG	N202088 002	Jun 13, 2011	Apr	CRLD
>A>			30MG	N202088 002	Jun 13, 2011	Apr	CRLD
>D>			37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
>A>	+		37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
			37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

PHENTERMINE RESIN COMPLEX

## CAPSULE, EXTENDED RELEASE; ORAL

## PHENTERMINE RESIN COMPLEX

+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHYTONADIONE

## INJECTABLE; INJECTION

## PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD
----	---	-----------------	-----------	-------------	--	-----	------

PIOGLITAZONE HYDROCHLORIDE

## TABLET; ORAL

## ACTOS

		TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
			EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
	+		EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN

POTASSIUM CHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## K+10

		@ FUTURE PAK	10MEQ	A070999 001	Oct 22, 1987	Mar	DISC
		KAON CL-10					
		@ SAVAGE LABS	10MEQ	N017046 002		Mar	DISC
		KLOR-CON M20					
AB	+	UPSHER-SMITH LABS	20MEQ	A074726 001	Nov 20, 1998	Mar	CRLD
		KLOTRIX					
		@ APOTHECON	10MEQ	N017850 001		Mar	DISC
		POTASSIUM CHLORIDE					
		@ NESHER PHARMS	20MEQ	A076044 001	Apr 05, 2002	Mar	DISC
		@ SCHERING	10MEQ	N019439 002	Jun 13, 1986	Mar	DISC
		@	20MEQ	N019439 001	Jun 13, 1986	Mar	DISC

POTASSIUM CITRATE

## FOR SOLUTION; ORAL

## POTASSIUM CITRATE

		@ NOVA K	10MEQ/PACKET	N019647 002	Oct 13, 1988	Feb	CAHN
		@	20MEQ/PACKET	N019647 001	Oct 13, 1988	Feb	CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

## TABLET; ORAL

## PRAMIPEXOLE DIHYDROCHLORIDE

>A>	AB	APOTEX INC	0.125MG	A090151 001	Apr 30, 2012	Apr	NEWA
>A>	AB		0.25MG	A090151 002	Apr 30, 2012	Apr	NEWA
>A>	AB		0.5MG	A090151 003	Apr 30, 2012	Apr	NEWA
>A>	AB		0.75MG	A090151 006	Apr 30, 2012	Apr	NEWA
>A>	AB		1MG	A090151 004	Apr 30, 2012	Apr	NEWA
>A>	AB		1.5MG	A090151 005	Apr 30, 2012	Apr	NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

>D>	AB	RANBAXY	10MG	A076445 001	Apr 23, 2007	Apr	DISC
>D>	AB		20MG	A076445 002	Apr 23, 2007	Apr	DISC
>D>	AB		40MG	A076445 003	Apr 23, 2007	Apr	DISC
>D>	AB		80MG	A076445 004	Apr 23, 2007	Apr	DISC
>A>		@ RANBAXY LABS LTD	10MG	A076445 001	Apr 23, 2007	Apr	DISC
>A>		@	20MG	A076445 002	Apr 23, 2007	Apr	DISC
>A>		@	40MG	A076445 003	Apr 23, 2007	Apr	DISC
>A>		@	80MG	A076445 004	Apr 23, 2007	Apr	DISC

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077287 001	Sep 19, 2006	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

PREDNICARBATE

AB		FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

PREGABALIN

CAPSULE; ORAL

LYRICA

PF PRISM

			25MG	N021446 001	Dec 30, 2004	Jan	CAHN
			50MG	N021446 002	Dec 30, 2004	Jan	CAHN
			75MG	N021446 003	Dec 30, 2004	Jan	CAHN
			100MG	N021446 004	Dec 30, 2004	Jan	CAHN
			150MG	N021446 005	Dec 30, 2004	Jan	CAHN
			200MG	N021446 006	Dec 30, 2004	Jan	CAHN
			225MG	N021446 007	Dec 30, 2004	Jan	CAHN
		+	300MG	N021446 008	Dec 30, 2004	Jan	CAHN

SOLUTION; ORAL

LYRICA

		+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan	CAHN
--	--	---	----------	---------	-------------	--------------	-----	------

PROGESTERONE

CAPSULE; ORAL

PROGESTERONE

AB		TEVA PHARMS	100MG	A202121 001	Feb 29, 2012	Feb	NEWA
----	--	-------------	-------	-------------	--------------	-----	------

AB			200MG	A202121 002	Feb 29, 2012	Feb	NEWA
----	--	--	-------	-------------	--------------	-----	------

PROMETRIUM

AB		ABBOTT LABS	100MG	N019781 001	May 14, 1998	Feb	CFTG
----	--	-------------	-------	-------------	--------------	-----	------

AB		+	200MG	N019781 002	Oct 15, 1999	Feb	CFTG
----	--	---	-------	-------------	--------------	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB		ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar	NEWA
----	--	---------------------	--------------	-------------	--------------	-----	------

AB			EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar	NEWA
----	--	--	--------------	-------------	--------------	-----	------

AB			EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB			EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
----	--	--	---------------	-------------	--------------	-----	------

AB		APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
----	--	------------	--------------	-------------	--------------	-----	------

AB			EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
----	--	--	--------------	-------------	--------------	-----	------

## TABLET; ORAL

## QUETIAPINE FUMARATE

AB	APOTEX INC	EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA
	SEROQUEL					
AB	+ ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG

## TABLET; ORAL

## SEROQUEL

AB	ASTRAZENECA	EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

RAMIPRIL

## CAPSULE; ORAL

## RAMIPRIL

>D>	AB	RANBAXY	5MG	A078849 001	Mar 06, 2009	Apr	DISC
>D>	AB		10MG	A078849 002	Mar 06, 2009	Apr	DISC
>A>		@ RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009	Apr	DISC
>A>		@	10MG	A078849 002	Mar 06, 2009	Apr	DISC

## TABLET; ORAL

## ALTACE

@ KING PFIZER

@

@

@

1.25MG  
2.5MG  
5MG  
10MG

N022021 001 Feb 27, 2007 Jan DISC  
N022021 002 Feb 27, 2007 Jan DISC  
N022021 003 Feb 27, 2007 Jan DISC  
N022021 004 Feb 27, 2007 Jan DISC

RANITIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
		ZANTAC IN PLASTIC CONTAINER					
	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
		@	EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN

RIFAMPIN

## CAPSULE; ORAL

## RIMACTANE

AB		PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	--	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

## TABLET; ORAL

## EDURANT

	+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
--	---	---------------	--------------	-------------	--------------	-----	------

RISPERIDONE

## TABLET; ORAL

## RISPERIDONE

AB		PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB			0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB			1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB			2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB			3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB			4MG	A078071 006	Jun 17, 2009	Feb	CMFD

## TABLET, ORALLY DISINTEGRATING; ORAL

## RISPERIDONE

AB		TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB			1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB			2MG	A076908 003	Mar 12, 2012	Feb	NEWA



ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB	APOTEX	EQ 0.25MG BASE	A079165 001	Feb 07, 2012	Jan	NEWA
AB		EQ 0.5MG BASE	A079165 002	Feb 07, 2012	Jan	NEWA
AB		EQ 1MG BASE	A079165 003	Feb 07, 2012	Jan	NEWA
AB		EQ 2MG BASE	A079165 004	Feb 07, 2012	Jan	NEWA
AB		EQ 3MG BASE	A079165 005	Feb 07, 2012	Jan	NEWA
AB		EQ 4MG BASE	A079165 006	Feb 07, 2012	Jan	NEWA
AB		EQ 5MG BASE	A079165 007	Feb 07, 2012	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

>D>	+	SMITHKLINE BEECHAM	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
>A>	AB	+	EQ 2MG BASE	N022008 001	Jun 13, 2008	Apr	CFTG
>D>			EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
>A>	AB		EQ 4MG BASE	N022008 003	Jun 13, 2008	Apr	CFTG
>D>			EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
>A>	AB		EQ 6MG BASE	N022008 006	Apr 10, 2009	Apr	CFTG
>D>			EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
>A>	AB		EQ 8MG BASE	N022008 004	Jun 13, 2008	Apr	CFTG
>D>			EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG
>A>	AB		EQ 12MG BASE	N022008 005	Oct 31, 2008	Apr	CFTG
>A>		ROPINIROLE HYDROCHLORIDE					
>A>	AB	ACTAVIS	EQ 2MG BASE	A090869 001	May 17, 2012	Apr	NEWA
>A>	AB		EQ 4MG BASE	A090869 002	May 17, 2012	Apr	NEWA
>A>	AB		EQ 6MG BASE	A090869 003	May 17, 2012	Apr	NEWA
>A>	AB		EQ 8MG BASE	A090869 004	May 17, 2012	Apr	NEWA
>A>	AB		EQ 12MG BASE	A090869 005	May 17, 2012	Apr	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

>A>		UCB INC	1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
>D>		@	2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
>A>			2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
>A>			3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
>D>		@	4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
>A>			4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
>D>		@	6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
>A>			6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
>A>		+	8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jan	CAHN
---	--------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

AB	PROSAM LABS	EQ 25MG BASE	A078175 001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175 002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175 003	Jul 21, 2010	Feb	CMFD

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT INC

460MG/GM;420MG/GM

N018509 001 Aug 07, 1985 Jan CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP	HIKMA (MAPLE)	9MG/ML	A201850 001	Jan 20, 2012	Jan	NEWA
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
	MEDEFIL	9MG/ML	N202832 001	Jan 06, 2012	Jan	NEWA

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

9-100mCi

N021305 006 May 19, 2005 Feb CAHN

@

2-200mCi

N021305 004 Nov 18, 2004 Jan DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE

1-250mCi/0.25ML

N021305 002 Jan 24, 2003 Feb DISC

@

1-1000mCi/ML

N021305 005 Apr 04, 2006 Feb DISC

@

1-500mCi/0.5ML

N021305 003 Jan 24, 2003 Feb DISC

+

250-1000mCi

N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+ HOPE PHARMS

300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012 Feb NEWA

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS

12.5GM/50ML (250MG/ML)

N203923 001 Feb 14, 2012 Feb NEWA

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK LLC

100MG

N019998 002 Jan 30, 1991 Mar CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB	FOUGERA PHARMS	10%	A077015 001	Nov 17, 2006	Jan	CAHN
----	----------------	-----	-------------	--------------	-----	------

SULFANILAMIDE

CREAM; VAGINAL

AVC

+ JAZZ PHARMS COMMERCL 15% N006530 003 Jan 27, 1987 Mar CAHN

SUPPOSITORY; VAGINAL

AVC

@ JAZZ PHARMS COMMERCL 1.05GM N006530 004 Jan 27, 1987 Mar CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

SUMATRIPTAN SUCCINATE

AP INJECTALIA EQ 6MG BASE/0.5ML (EQ 12MG  
BASE/ML) A090310 001 Aug 11, 2010 Mar CAHNTAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+ MERCK SHARP DOHME 0.0015% N202514 001 Feb 10, 2012 Feb NEWA

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+ GILEAD SCIENCES INC 40MG/SCOOPFUL N022577 001 Jan 18, 2012 Jan NEWA

TABLET; ORAL

VIREAD

&gt;A&gt; GILEAD SCIENCES INC 150MG N021356 002 Jan 18, 2012 Apr NEWA

&gt;A&gt; 200MG N021356 003 Jan 18, 2012 Apr NEWA

&gt;A&gt; 250MG N021356 004 Jan 18, 2012 Apr NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

&gt;D&gt; AB RANBAXY EQ 1MG BASE A076021 001 Aug 22, 2002 Apr DISC

&gt;D&gt; AB EQ 2MG BASE A076021 002 Aug 22, 2002 Apr DISC

&gt;D&gt; AB EQ 5MG BASE A076021 003 Aug 22, 2002 Apr DISC

&gt;D&gt; AB EQ 10MG BASE A076021 004 Aug 22, 2002 Apr DISC

&gt;A&gt; @ RANBAXY LABS LTD EQ 1MG BASE A076021 001 Aug 22, 2002 Apr DISC

&gt;A&gt; @ EQ 2MG BASE A076021 002 Aug 22, 2002 Apr DISC

&gt;A&gt; @ EQ 5MG BASE A076021 003 Aug 22, 2002 Apr DISC

&gt;A&gt; @ EQ 10MG BASE A076021 004 Aug 22, 2002 Apr DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

@ TEVA PARENTERAL 1MG/ML A076853 001 Jul 20, 2004 Jan DISC

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB FOUGERA PHARMS 0.4% A076712 001 Feb 18, 2005 Jan CAHN

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB FOUGERA PHARMS 80MG A076850 001 Jul 12, 2006 Jan CAHN

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

BX	+	ABBOTT LABS	1% (50MG/5GM PACKET)	N021015 002	Feb 28, 2000	Feb	CPOT
			1% (25MG/2.5GM PACKET)	N021015 001	Feb 28, 2000	Feb	CPOT

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454 001	Oct 31, 2002	Feb	CPOT
----	---	-----------------	----------------------	-------------	--------------	-----	------

TESTOSTERONE

TEVA PHARMS

25MG/2.5GM PACKET

N202763 001	Feb 14, 2012	Feb	NEWA
-------------	--------------	-----	------

50MG/5GM PACKET

N202763 002	Feb 14, 2012	Feb	NEWA
-------------	--------------	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

>A>	AO	HIKMA FARMACEUTICA	200MG/ML	A091244 001	May 01, 2012	Apr	NEWA
	AO	MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

AO		MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009	Feb	CAHN
----	--	---------------------	----------	-------------	--------------	-----	------

TETRABENAZINE

TABLET; ORAL

XENAZINE

>D>		VALEANT INTL	12.5MG	N021894 001	Aug 15, 2008	Apr	CAHN
>D>	+		25MG	N021894 002	Aug 15, 2008	Apr	CAHN
>A>		VALEANT PHARMS	12.5MG	N021894 001	Aug 15, 2008	Apr	CAHN
>A>	+		25MG	N021894 002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%	A086576 002		Jan	CAHN
		0.1%	A086576 001		Jan	CAHN

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%	A086576 003		Jan	CAHN
---	----------------	------	-------------	--	-----	------

THEOPHYLLINE

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
@		40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
@		80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
@		160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
@		200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
@		320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
@		400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@	CEPHALON	6MG	N020646 006	Nov 29, 2005	Jan	DISC
@		8MG	N020646 007	Nov 29, 2005	Jan	DISC

## TABLET; ORAL

GABITRIL

@ CEPHALON

10MG

N020646 008 Nov 29, 2005 Jan DISC

TINIDAZOLE

## TABLET; ORAL

TINDAMAX

>D>		MISSION PHARMA	250MG	N021618 001	May 17, 2004	Apr	CFTG
>A>	AB		250MG	N021618 001	May 17, 2004	Apr	CFTG
>D>		+	500MG	N021618 002	May 17, 2004	Apr	CFTG
>A>	AB	+	500MG	N021618 002	May 17, 2004	Apr	CFTG
>A>		TINIDAZOLE					
>A>	AB	NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012	Apr	NEWA
>A>	AB		500MG	A202044 002	Apr 30, 2012	Apr	NEWA
>A>	AB	ROXANE	250MG	A201172 001	Apr 30, 2012	Apr	NEWA
>A>	AB		500MG	A201172 002	Apr 30, 2012	Apr	NEWA

TIZANIDINE HYDROCHLORIDE

## CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB		APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
AB			EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB			EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
		ZANAFLEX					
AB		ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB			EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB		+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

## TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB		PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
AB			EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
AB		SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOLBUTAMIDE

## TABLET; ORAL

TOLBUTAMIDE

+		MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
		@ WATSON LABS	500MG	A086109 001		Mar	DISC
		@	500MG	A087318 001		Mar	DISC

TRAMADOL HYDROCHLORIDE

## TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+		SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

## INJECTABLE; INJECTION

TRANEXAMIC ACID

AP		NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA
----	--	--------------	----------	-------------	--------------	-----	------

TRANLYCYPROMINE SULFATE

## TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	-------------	--------------	-----	------

TRETINOIN

CREAM; TOPICAL		RENOVA							
	+	VALEANT INTL	0.02%	N021108	001	Aug 31, 2000	Jan	CAHN	
AB2	+		0.05%	N019963	001	Dec 29, 1995	Jan	CAHN	
RETIN-A									
AB	+	VALEANT INTL	0.025%	N019049	001	Sep 16, 1988	Jan	CAHN	
AB1	+		0.05%	N017522	001		Jan	CAHN	
AB	+		0.1%	N017340	001		Jan	CAHN	
GEL; TOPICAL		RETIN-A							
AB	+	VALEANT INTL	0.01%	N017955	001		Jan	CAHN	
AB	+		0.025%	N017579	002		Jan	CAHN	
SOLUTION; TOPICAL		RETIN-A							
AT	+	VALEANT INTL	0.05%	N016921	001		Jan	CAHN	
SWAB; TOPICAL		RETIN-A							
	@	VALEANT INTL	0.05%	N016921	002		Jan	CAHN	

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL		TRIAMCINOLONE ACETONIDE							
AT		FOUGERA PHARMS	0.025%	A085692	001		Jan	CAHN	
AT			0.1%	A085692	003		Jan	CAHN	
AT	+		0.5%	A085692	002		Jan	CAHN	
LOTION; TOPICAL		TRIAMCINOLONE ACETONIDE							
AT		FOUGERA PHARMS	0.025%	A040467	001	Apr 21, 2003	Jan	CAHN	
AT			0.1%	A040467	002	Apr 21, 2003	Jan	CAHN	
OINTMENT; TOPICAL		TRIAMCINOLONE ACETONIDE							
AT		FOUGERA PHARMS	0.025%	A085691	001		Jan	CAHN	
AT			0.1%	A085691	003		Jan	CAHN	
AT			0.5%	A085691	002		Jan	CAHN	
SPRAY, METERED; NASAL		TRIAMCINOLONE ACETONIDE							
AB		TEVA PHARMS	0.055MG/SPRAY	A078104	001	Jul 30, 2009	Mar	CAHN	

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL		VALACYCLOVIR HYDROCHLORIDE							
AB		JUBILANT ORGANOSYS	EQ 500MG BASE	A201506	001	Apr 03, 2012	Mar	NEWA	
AB			EQ 1GM BASE	A201506	002	Apr 03, 2012	Mar	NEWA	

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL		VANCOCIN HYDROCHLORIDE							
AB		VIROPHARMA	EQ 125MG BASE	N050606	001	Apr 15, 1986	Mar	CFTG	
AB	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	Mar	CFTG	
VANCOMYCIN HYDROCHLORIDE									
AB		AKORN	EQ 125MG BASE	A065478	001	Apr 09, 2012	Mar	NEWA	
AB			EQ 250MG BASE	A065478	002	Apr 09, 2012	Mar	NEWA	
AB		STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490	001	Apr 09, 2012	Mar	NEWA	
AB			EQ 250MG BASE	A065490	002	Apr 09, 2012	Mar	NEWA	

## CAPSULE; ORAL

## VANCOMYCIN HYDROCHLORIDE

AB	WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA

VANDETANIB

## TABLET; ORAL

## CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
+		300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

## TABLET; ORAL

## LEVITRA

>D>	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG	
>A>	AB	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG	
>D>		5MG	N021400 001	Aug 19, 2003	Apr	CFTG	
>A>	AB	5MG	N021400 001	Aug 19, 2003	Apr	CFTG	
>D>		10MG	N021400 002	Aug 19, 2003	Apr	CFTG	
>A>	AB	10MG	N021400 002	Aug 19, 2003	Apr	CFTG	
>D>	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG	
>A>	AB +	20MG	N021400 004	Aug 19, 2003	Apr	CFTG	
>A>	VARDENAFIL HYDROCHLORIDE						
>A>	AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
>A>	AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
>A>	AB		10MG	A091347 003	May 03, 2012	Apr	NEWA
>A>	AB		20MG	A091347 004	May 03, 2012	Apr	NEWA

VENLAFAXINE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE; ORAL

## VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

VERAPAMIL HYDROCHLORIDE

## TABLET, EXTENDED RELEASE; ORAL

## CALAN SR

AB	+	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB	+		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB	+		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

## VERAPAMIL HYDROCHLORIDE

>A>	AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
>A>	AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
>A>	AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

## FOR SOLUTION; ORAL

## SABRIL

>D>	+	LUNDBECK INC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
>A>	+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN

## TABLET; ORAL

## SABRIL

>D>	+	LUNDBECK INC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
>A>	+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VILIBRYD

>D>		FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
>A>	+		10MG	N022567 001	Jan 21, 2011	Apr	CRLD
>D>	+		40MG	N022567 003	Jan 21, 2011	Apr	CRLD
>A>			40MG	N022567 003	Jan 21, 2011	Apr	CRLD

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388 001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	-------------	--------------	-----	------

VORICONAZOLE

TABLET; ORAL

VORICONAZOLE

AB	TEVA PHARMS	50MG	A091658 001	Apr 06, 2012	Mar	NEWA
AB		200MG	A091658 002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@	JAZZ PHARMS COMMERCL	200MCG/2ML (100MCG/ML)	N021060 003	Dec 28, 2004	Mar	CAHN
---	----------------------	------------------------	-------------	--------------	-----	------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060 002	Dec 28, 2004	Mar	CAHN
+		500MCG/5ML (100MCG/ML)	N021060 004	Dec 28, 2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060 001	Dec 28, 2004	Mar	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

>D>	AB	RANBAXY	300MG	A077327 001	Sep 19, 2005	Apr	DISC
>A>		@ RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825 001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825 002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825 003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825 004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561 004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565 004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560 002	Mar 02, 2012	Feb	NEWA



## CAPSULE; ORAL

## ZIPRASIDONE HYDROCHLORIDE

AB	LUPIN PHARMS	EQ 60MG BASE	A077560 003	Mar 02, 2012	Feb	NEWA
AB		EQ 80MG BASE	A077560 004	Mar 02, 2012	Feb	NEWA

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+ MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN
---------------	------------------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORASCORB MAXI SWABSTICK

+ PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
--------------	-------------------	---------	-----	--------------	-----	------

CHLORASCORB SWAB

+ PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
--------------	-----------------	---------	-----	--------------	-----	------

CHLORASCORB SWABSTICK

+ PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN
--------------	-------------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD 25MG;EQ 200MG FREE ACID AND  
POTASSIUM SALT

A200888	001	Mar 05, 2012	Feb	NEWA
---------	-----	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS

10MG

N020801	001	Sep 24, 1998	Mar	CAHN
---------	-----	--------------	-----	------

+	20MG	N020801	002	Dec 17, 2007	Mar	CAHN
---	------	---------	-----	--------------	-----	------

TABLET; ORAL

PEPCID AC

MCNEIL CONS

10MG

N020325	001	Apr 28, 1995	Mar	CAHN
---------	-----	--------------	-----	------

+	20MG	N020325	002	Sep 23, 2003	Mar	CAHN
---	------	---------	-----	--------------	-----	------

PEPCID AC (GELTAB)

MCNEIL CONS

10MG

N020902	001	Aug 05, 1999	Mar	CAHN
---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS

30MG

A091567	002	Feb 06, 2012	Jan	NEWA
---------	-----	--------------	-----	------

WOCKHARDT LTD

30MG

A079112	002	Feb 08, 2012	Jan	NEWA
---------	-----	--------------	-----	------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS

30MG

A091567	001	Feb 06, 2012	Jan	NEWA
---------	-----	--------------	-----	------

WOCKHARDT LTD

30MG

A079112	001	Feb 08, 2012	Jan	NEWA
---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS

60MG

A091567	004	Feb 06, 2012	Jan	NEWA
---------	-----	--------------	-----	------

180MG

A091567	006	Feb 06, 2012	Jan	NEWA
---------	-----	--------------	-----	------

WOCKHARDT LTD

60MG

A079112	004	Feb 08, 2012	Jan	NEWA
---------	-----	--------------	-----	------

180MG

A079112	006	Feb 08, 2012	Jan	NEWA
---------	-----	--------------	-----	------

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS

60MG

A091567	003	Feb 06, 2012	Jan	NEWA
---------	-----	--------------	-----	------

180MG

A091567	005	Feb 06, 2012	Jan	NEWA
---------	-----	--------------	-----	------

WOCKHARDT LTD

60MG

A079112	003	Feb 08, 2012	Jan	NEWA
---------	-----	--------------	-----	------

180MG

A079112	005	Feb 08, 2012	Jan	NEWA
---------	-----	--------------	-----	------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338 001	Jul 10, 2009	Jan	CAHN
---------------	---------------------------------------	-------------	--------------	-----	------

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

>A>	DR REDDYS LABS LTD	15MG	A202194 001	May 18, 2012	Apr	NEWA
>A>	FERRIGO R AND D	15MG	A202319 001	May 18, 2012	Apr	NEWA
>A>	WOCKHARDT LTD	15MG	A202727 001	May 18, 2012	Apr	NEWA
	PREVACID 24 HR					
>D>	+ NOVARTIS	15MG	N022327 001	May 18, 2009	Apr	CFTG
>A>	+	15MG	N022327 001	May 18, 2009	Apr	CFTG

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

>A>	AVEVA	7MG/24HR	A074612 002	Jul 28, 2003	Apr	NEWA
>A>		14MG/24HR	A074612 003	Oct 20, 1997	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

SHASUN CHEMS	EQ 75MG BASE	A201745 001	Feb 29, 2012	Feb	NEWA
--------------	--------------	-------------	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2012**

NO APRIL 2012 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2012 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	8110706	Nov 09, 2021	DP			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001					>A> NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 002					>A> NCE	Apr 27, 2017
<u>AVANAFIL - STENDRA</u>						
N202276 003					>A> NCE	Apr 27, 2017
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BIMATOPROST - LATISSE</u>						
N022369 001	>A> 8101161	May 25, 2024	U-1218			
	>A> 8101161	May 25, 2024	U-1217			
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N022258 001	8119602	Mar 17, 2027	U-1233			
	>A> RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	>A> 8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	>A> 8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	>A> 6022562	Oct 17, 2015	DP		Y	
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	>A> 6022562	Oct 17, 2015	DP		Y	
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	>A> 6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	>A> 6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028		U-1161		
	8097655	Oct 06, 2028		U-1020		
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016		U-935		
	6037157	Jun 26, 2016		U-1209		
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016		U-935		
	6703403	Jun 26, 2016		U-1209		
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019		U-935		
	7470506	Jun 23, 2019		U-1209		
	7470506*PED	Dec 23, 2019				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-935			
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	>A> 8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001					>A> NCE	May 20, 2016
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ETRAVIRINE - INTELENCE</u>						
N022187 001	>A> 6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	>A> 6878717	Nov 05, 2019	U-1237			
	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 7037917	Dec 13, 2020	DS DP U-256			
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7037917	Dec 13, 2020	DS DP U-1016			
<u>ETRAVIRINE - INTELENCE</u>						
N022187 002	>A> 6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	>A> 6878717	Nov 05, 2019	U-1237			
	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 7037917	Dec 13, 2020	DS DP U-256			
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7037917	Dec 13, 2020	DS DP U-1016			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETRAVIRINE - INTELENCE</u>						
N022187 003	>A> 6878717	Nov 05, 2019	U-256		NPP	Mar 26, 2015
	>A> 6878717	Nov 05, 2019	U-1237		NCE	Jan 18, 2013
	>A> 6878717	Nov 05, 2019	U-1016			
	>A> 7037917	Dec 13, 2020	DS DP U-1237			
	>A> 7887845	Mar 25, 2019	DP			
	>A> 8003789	Nov 01, 2019	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N022334 001					>A> I-650	Apr 26, 2015
<u>EVEROLIMUS - AFINITOR</u>						
N022334 002					>A> I-650	Apr 26, 2015
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003					>A> I-650	Apr 26, 2015
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	>A> 5665772	Sep 09, 2019	DS DP		>A> I-650	Apr 26, 2015
	>A> 6004973	Jul 12, 2016	DP		>A> I-638	May 05, 2014
	>A> 7297703	Dec 06, 2019	DP		>A> I-630	Oct 29, 2013
					>A> NCE	Mar 30, 2014
					>A> ODE	May 05, 2018
					>A> ODE	Oct 29, 2017
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 002					M-113	Oct 19, 2014
					M-111	Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 001					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 002					M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687 003					M-109	Jan 24, 2015

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	004				M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003				M-112	Feb 09, 2015
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	001	8124125	Oct 01, 2024	DP U-1234		
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	002	8124125	Oct 01, 2024	DP U-1234		
<u>FENTANYL - SUBSYS</u>						
N202788	001				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	002				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	003				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	004				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	005				NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	001	8092832	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	002	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	003	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	004	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	005	8092832	Dec 30, 2024	DP		
		8119158	Dec 30, 2024	DP		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030	001	8088398	Jun 07, 2027	DP U-913		
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030	002	8088398	Jun 07, 2027	DP U-913		
<u>FINGOLIMOD - GILENYA</u>						
N022527	001	>A> 6004565	Sep 23, 2017	U-1086		

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	>A> 7687052	Apr 30, 2027	DS DP		>A> NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	>A> 7687052	Apr 30, 2027	DS DP		>A> NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	>A> 7687052	Apr 30, 2027	DS DP		>A> NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					>A> NPP >A> PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					>A> NPP >A> PED	Apr 27, 2015 Oct 27, 2015
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8114909	Apr 11, 2026		U-1231		
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8114909	Apr 11, 2026		U-1231		
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVIIST</u>						
N022090 001	>A> 5798092	Apr 25, 2015	DS DP			
	>A> 6039931	Nov 13, 2021		U-1239		
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					>A> PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					>A> PC	Sep 26, 2012
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001					>A> M-115	Apr 06, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					>A> PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					>A> PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					>A> PC	Sep 26, 2012
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023	U-1216			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS U-1211			
	6045501	Aug 28, 2018	U-1210			
	6281230	Jul 24, 2016	U-1212			
	6315720	Oct 23, 2020	U-1210			
	6555554	Jul 24, 2016	DP U-1211			
	6561976	Aug 28, 2018	U-1210			
	6561977	Oct 23, 2020	U-1210			
	6755784	Oct 23, 2020	U-1210			
	6908432	Aug 28, 2018	U-1210			
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023	U-1215			
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023	U-1216			
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	8119648	Aug 12, 2023	U-774			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		>A> M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	>A> 5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					>A> D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002					>A> D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003					>A> D-134	Apr 26, 2015
					>A> NCE	Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004					>A> D-134	Apr 26, 2015
					>A> NCE	Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	>A> 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	>A> 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	>A> 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	>A> 8163798	Jul 31, 2017	DP			
	>A> 8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830	001				NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830	002				NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409	001				NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	001	>A> 8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	002	>A> 8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	003	>A> 8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	004	>A> 8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	005	>A> 8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	006	>A> 8158156	Jun 19, 2027	U-1241		
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599	002				NS	Jan 13, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165	004	8075911	May 22, 2021	DP		
<u>NICOTINE - NICODERM CQ</u>						
N020165	005	8075911	May 22, 2021	DP		
<u>NICOTINE - NICODERM CQ</u>						
N020165	006	8075911	May 22, 2021	DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068	001	>A> 8163904	Aug 23, 2028	DS DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068	002	>A> 8163904	Aug 23, 2028	DS DP		
<u>NITRIC OXIDE - INOMAX</u>						
N020845	002	5558083	Nov 22, 2013	DP	U-1226	
		5558083*PED	May 22, 2014			
		5732693	Dec 13, 2016	DP	U-1230	
		5732693*PED	Jun 13, 2017			
		5752504	Dec 13, 2016	DP	U-1230	
		5752504*PED	Jun 13, 2017			
<u>NITRIC OXIDE - INOMAX</u>						
N020845	003	5558083	Nov 22, 2013	DP	U-1226	
		5558083*PED	May 22, 2014			
		5732693	Dec 13, 2016	DP	U-1230	
		5732693*PED	Jun 13, 2017			
		5752504	Dec 13, 2016	DP	U-1230	
		5752504*PED	Jun 13, 2017			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	>A> 7029694	Apr 26, 2020	DP U-318			
	>A> 7179483	Apr 26, 2020	U-318			
	>A> 7198801	Jun 25, 2022	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	8138229	Dec 09, 2023	DP U-1092			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005					>A> NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006					>A> NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP		>A> I-649 >A> ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP		>A> I-649 >A> ODE	Apr 26, 2015 Apr 26, 2017
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	>A> 7084245	May 12, 2024	DS DP	U-1238		
	>A> 7414105	May 12, 2024	DS DP	U-1238		
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026		U-1238		
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	>A> 7084245	May 12, 2024	DS DP	U-1238		
	>A> 7414105	May 12, 2024	DS DP	U-1238		
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026		U-1238		
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	>A> 7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP	U-1238		
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026		U-1238		
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026		U-1238		
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	>A> 7084245	May 12, 2024	DS DP	U-1238	NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP	U-1238		
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026		U-1238		
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026		U-1238		

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	>A> 7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	>A> 7414105	May 12, 2024	DS DP U-1238			
	>A> 7528104	May 12, 2024	DS DP			
	>A> 7550433	Jun 02, 2026	U-1238			
	>A> 7919118	May 12, 2024	DS DP			
	>A> 7919461	Jun 02, 2026	U-1238			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	>A> 7799331	Oct 11, 2028	DP U-139			
	>A> 7799331	Oct 11, 2028	DP U-1068			



## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	>A> 7799331	Oct 11, 2028	DP U-139			
	>A> 7799331	Oct 11, 2028	DP U-1068			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	>A> 8158644	Jun 19, 2024	DP			
	>A> 8158781	Jun 19, 2024	DS			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	>A> 8158644	Jun 19, 2024	DP			
	>A> 8158781	Jun 19, 2024	DS			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003					I-647 I-646	Apr 02, 2015 Apr 02, 2015
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	>A> 6699498	Nov 27, 2020	DP		>A> I-647	Apr 02, 2015
	>A> 6884434	Mar 30, 2021	DP		>A> I-646	Apr 02, 2015
	>A> 7413747	Mar 18, 2019	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	>A> 6699498	Nov 27, 2020	DP		>A> I-647	Apr 02, 2015
	>A> 6884434	Mar 30, 2021	DP		>A> I-646	Apr 02, 2015
	>A> 7413747	Mar 18, 2019	DP			

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	>A> 6699498	Nov 27, 2020	DP		>A> I-647	Apr 02, 2015
	>A> 6884434	Mar 30, 2021	DP		>A> I-646	Apr 02, 2015
	>A> 7413747	Mar 18, 2019	DP			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		NDF	Nov 20, 2012
	5250534*PED	Sep 27, 2012			PED	May 20, 2013
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019		U-155		
	6469012*PED	Apr 22, 2020				
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	8118771	Aug 10, 2023	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	8114383	Oct 10, 2024	DP			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	8114383	Oct 10, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	>A> 8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	>A> 8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		NCE	May 30, 2012
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
					PED	Nov 30, 2012
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001					NPP	Jan 18, 2015
					PED	Jul 18, 2015
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	>A> 5922695	Jul 25, 2017	DS U-250		>A> M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-256		>A> NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		>A> NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		>A> ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			>A> PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		>A> PED	Jul 18, 2015
	>A> 5935946	Jul 25, 2017	DS DP U-248		>A> PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-250		>A> PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 003	>A> 5922695	Jul 25, 2017	DS U-250		>A> M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-256		>A> NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		>A> NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		>A> ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			>A> PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		>A> PED	Jul 18, 2015
	>A> 5935946	Jul 25, 2017	DS DP U-248		>A> PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-250		>A> PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 004	>A> 5922695	Jul 25, 2017	DS U-250		>A> M-95	Oct 01, 2013
	>A> 5922695	Jul 25, 2017	DS U-256		>A> NPP	Jan 18, 2015
	>A> 5922695	Jul 25, 2017	DS U-999		>A> NPP	Mar 24, 2013
	>A> 5922695	Jul 25, 2017	DS U-248		>A> ODE	Mar 24, 2017
	>A> 5922695*PED	Jan 25, 2018			>A> PED	Sep 24, 2017
	>A> 5935946	Jul 25, 2017	DS DP U-999		>A> PED	Jul 18, 2015
	>A> 5935946	Jul 25, 2017	DS DP U-248		>A> PED	Apr 01, 2014
	>A> 5935946	Jul 25, 2017	DS DP U-250		>A> PED	Sep 24, 2013
	>A> 5935946	Jul 25, 2017	DS DP U-256			
	>A> 5935946*PED	Jan 25, 2018				
	>A> 5977089	Jul 25, 2017	DS DP U-250			
	>A> 5977089	Jul 25, 2017	DS DP U-256			
	>A> 5977089	Jul 25, 2017	DS DP U-999			
	>A> 5977089	Jul 25, 2017	DS DP U-248			
	>A> 5977089*PED	Jan 25, 2018				
	>A> 6043230	Jul 25, 2017	U-248			
	>A> 6043230	Jul 25, 2017	U-250			
	>A> 6043230	Jul 25, 2017	U-256			
	>A> 6043230	Jul 25, 2017	U-999			
	>A> 6043230*PED	Jan 25, 2018				

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-250		>A> M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-256		>A> NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-248		>A> ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			>A> PED	Sep 24, 2017
	5935946	Jul 25, 2017	DP U-999	Y	PED	Jul 18, 2015
	5935946	Jul 25, 2017	DP U-248	Y	>A> PED	Apr 01, 2014
	5935946	Jul 25, 2017	DP U-250	Y	>A> PED	Sep 24, 2013
	5935946	Jul 25, 2017	DP U-256	Y		
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	>A> 8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	>A> 8143283	Mar 01, 2013	U-1236			
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	>A> 8143283	Mar 01, 2013	U-1236			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	>A> 8143283	Mar 01, 2013	U-1236			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	>A> 8143283	Mar 01, 2013	U-1236			
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014

## PATENT &amp; EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 4 - April 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	>A> 8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	>A> 8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N202429 001	>A> 8143271	Jun 21, 2026	DS DP			
<u>VISMODEGIB - ERIVEDGE</u>						
N203388 001					NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023		U-892		

## Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31<sup>st</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>